

University of Montana

## ScholarWorks at University of Montana

---

Graduate Student Theses, Dissertations, &  
Professional Papers

Graduate School

---

1968

### Some aspects of steroid hormones biosynthesis by ovarian tissue of the Wilson's phalarope (*Steganopus tricolor*)

Ho-Jane Yu

*The University of Montana*

Follow this and additional works at: <https://scholarworks.umt.edu/etd>

**Let us know how access to this document benefits you.**

---

#### Recommended Citation

Yu, Ho-Jane, "Some aspects of steroid hormones biosynthesis by ovarian tissue of the Wilson's phalarope (*Steganopus tricolor*)" (1968). *Graduate Student Theses, Dissertations, & Professional Papers*. 6951. <https://scholarworks.umt.edu/etd/6951>

This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [scholarworks@mso.umt.edu](mailto:scholarworks@mso.umt.edu).

SOME ASPECTS OF STEROID HORMONES BIOSYNTHESIS BY OVARIAN TISSUE  
OF THE WILSON'S PHALAROPE (STEGANOPUS TRICOLOR)

by


Ho-Jane Yu


B.S. National Taiwan University, 1964

Presented in partial fulfillment of the requirements  
for the degree of  
Master of Science  
UNIVERSITY OF MONTANA

1968

Approved by:

  
Chairman, Board of Examiners

  
Dean, Graduate School

AUG 13 1968

Date

UMI Number: EP37752

All rights reserved

**INFORMATION TO ALL USERS**

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



UMI EP37752

Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.

Microform Edition © ProQuest LLC.

All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code



ProQuest LLC.  
789 East Eisenhower Parkway  
P.O. Box 1346  
Ann Arbor, MI 48106 - 1346

## ACKNOWLEDGMENTS

I wish to express my sincere appreciation to Dr. H. Richard Fevold, Associate Professor of Chemistry, University of Montana, for his advice, guidance, assistance, and checking of my English manuscript throughout the course of this research.

Appreciation is also due Dr. M. E. Magar, Assistant Professor of Chemistry, and Dr. E. W. Pfeiffer, Professor of Zoology, for their advice and assistance in writing this thesis. I am also grateful to Mr. J. S. Rice, laboratory assistant, for his help on gas chromatographic techniques.

A major portion of this investigation was supported by research grants to Dr. Fevold from National Science Foundation, grant number GB-2540.

H.J.Y.

PART A

CHARACTERIZATION AND IDENTIFICATION OF SOME POLAR PRODUCTS OF IN VITRO  
PREGN-5-ENE-3 $\beta$ ,17 $\alpha$ -DIOL-20-ONE (17 $\alpha$ -HYDROXYPREGNENOLONE) AND PREGN-4-ENE-  
17 $\alpha$ -OL-3,20-DIONE (17 $\alpha$ -HYDROXYPROGESTERONE) METABOLISM BY WILSON'S  
PHALAROPE OVARIAN TISSUE

TABLE OF CONTENTS

	PAGE
I. INTRODUCTION . . . . .	1
II. HISTORICAL REVIEW . . . . .	5
A. Biosynthesis of preg-4-ene-17 $\alpha$ ,20 $\alpha$ -3-one and pregn-4-ene-17 $\alpha$ ,20 $\beta$ -diol-3-one . . . . .	5
B. Biosynthesis of estrogen . . . . .	6
III. EXPERIMENTAL MATERIALS AND PROCEDURES . . . . .	17
A. Experimental animals . . . . .	17
B. Chemicals . . . . .	17
C. Equipment . . . . .	20
D. Procedures . . . . .	21
1. Paper chromatography . . . . .	21
2. Drying process . . . . .	21
3. Substrate preparations . . . . .	21
4. Tissue preparation . . . . .	22
5. Preparation of incubation flasks . . . . .	22
6. Incubation . . . . .	22
7. Extraction . . . . .	24
8. Product purification, isolation and identification . . . . .	24

	PAGE
IV. RESULTS . . . . .	29
A. Identification of metabolites $X_1$ and $X_2$ . . . . .	29
B. Partially characterized metabolites . . . . .	35
V. DISCUSSION . . . . .	47
VI. SUMMARY . . . . .	53
VII. BIBLIOGRAPHY . . . . .	54

## LIST OF TABLES

TABLE	PAGE
1. Phalarope ovaries used for incubation . . . . .	23
2. Chromatographic identification of X <sub>1</sub> . . . . .	33
3. Chromatographic identification of X <sub>2</sub> . . . . .	34
4. <sup>3</sup> H/ <sup>14</sup> C ratios of initial substrates and neutral metabolites X <sub>1</sub> , X <sub>2</sub> . . . . .	36
5. Percent recovery of estrogens in the isolation processes . . .	36
6. Retention time of gas chromatographic analysis of methoxy derivatives of #P <sub>2</sub> and #P <sub>3</sub> . . . . .	42
7. R <sub>f</sub> values of phenolic metabolite #P <sub>1</sub> -A . . . . .	44
8. R <sub>f</sub> values of phenolic metabolite #P <sub>1</sub> -B . . . . .	45
9. R <sub>f</sub> values of phenolic metabolite #P <sub>1</sub> -C . . . . .	46

## LIST OF ILLUSTRATIONS

FIGURE	PAGE
1. Seasonal changes in androgen secretion by phalarope gonadal tissues (hypothetical curves) . . . . .	3
2. Biosynthesis of androgens . . . . .	10
3. Biosynthesis of estrogens from C-19 steroids . . . . .	13
4. Interrelationship of estrone and 17 $\beta$ -estradiol with 16 and 17 substituted phenolic estrogens . . . . .	16
5. Tracing of the first chromatographic separation of radio- active neutral metabolites isolated from incubations of phalarope ovarian tissues cell-free homogenate with 17 $\alpha$ - hydroxypregnenolone-7 $\alpha$ - <sup>3</sup> H and 17 $\alpha$ -hydroxyprogesterone- 4- <sup>14</sup> C . . . . .	30
6. Purification of neutral steroids in the benzene/formamide system by paper chromatography . . . . .	31
7. Procedure used for isolation and identification of X <sub>1</sub> and X <sub>2</sub> .	32
8. Procedure used for isolation of phenolic metabolites from phalarope ovarian tissue homogenate incubations . . . . .	37
9. Tracing of the first paper chromatogram of phenolic metabo- lites isolated from incubation of phalarope ovarian tissues cell-free homogenate with 17 $\alpha$ -hydroxypregnenolone- 7- $\alpha$ - <sup>3</sup> H and 17 $\alpha$ -hydroxyprogesterone-4- <sup>14</sup> C in the benzene/ formamide system . . . . .	38
10. Tracing of paper chromatogram of phenolic metabolite #P <sub>1</sub> fraction in the chloroform/formamide system . . . . .	38



FIGURE	PAGE
11. Effluent patterns of estrone and 17 $\beta$ -estradiol in silica gel column with different polarity of eluting solvents . . . . .	39
12. Thin-layer chromatogram of methylated estrogen samples in the benzene;methanol (99:1 v/v) system . . . . .	40

PART B

IN VITRO STUDIES OF  $17\beta$ -HYDROXYSTEROID DEHYDROGENASE ACTIVITY IN  
AVIAN OVARIAN AND TESTICULAR TISSUES

TABLE OF CONTENTS

	PAGE
I. INTRODUCTION . . . . .	63
II. HISTORICAL REVIEW . . . . .	65
A. Avian gonadal cycles . . . . .	65
B. $17\beta$ -Hydroxysteroid dehydrogenase . . . . .	71
III. EXPERIMENTAL MATERIALS AND PROCEDURES . . . . .	72
A. Experimental animals . . . . .	72
B. Chemicals . . . . .	73
C. Equipment . . . . .	73
D. Procedures . . . . .	73
1. Substrate preparation . . . . .	73
2. Tissue preparation . . . . .	73
3. Preparation of incubation flask . . . . .	74
4. Incubation . . . . .	74
5. Extraction . . . . .	76
6. Product purification, isolation and identification	76
7. Quantification of metabolites. . . . .	79
IV. RESULTS . . . . .	80
A. Effect of substrate concentration on the velocity of the $17\beta$ -hydroxysteroid dehydrogenase reaction in the ovarian and testicular tissues . . . . .	80

B. Rate of formation of testosterone from andro-  
stenedione in phalarope ovarian and testicular  
tissue . . . . . 80

C. Product identification . . . . . 88

V. DISCUSSION . . . . . 95

VI. SUMMARY . . . . . 104

VII. BIBLIOGRAPHY . . . . . 105

## LIST OF TABLES

TABLE	PAGE
1. Phalarope gonadal tissues used for incubations . . . . .	75
2. Total radioactivity of substrate and initial extraction standard added to the incubation flask before and after incubation, respectively . . . . .	77
3. Effect of varying ovarian weight on conversion of andro- stenedione substrate to testosterone . . . . .	82
4. Effect of varying testicular weight on conversion of androstenedione substrate to testosterone . . . . .	84
5. Effect of gonadal weight on 17 $\beta$ -hydroxysteroid dehydro- genase activity . . . . .	85
6. Chromatographic identification of metabolite I . . . . .	93
7. $^3\text{H}/^{14}\text{C}$ ratios of metabolite I . . . . .	94

## LIST OF ILLUSTRATIONS

FIGURE	PAGE
1. Typical annual gonadal cycle of English sparrow (modified from Witschi 1935) . . . . .	67
2. Tracing of the first chromatographic separation of radioactive metabolites isolated from incubations of phalarope gonadal tissues cell-free homogenate with androstenedione-4- <sup>14</sup> C as substrate . . . . .	78
3. Effect of substrate concentration on the velocity of the 17 $\beta$ -hydroxysteroid dehydrogenase reaction in phalarope gonadal tissues . . . . .	81
4. 17 $\beta$ -Hydroxysteroid dehydrogenase activity per 100 mg of incubation tissue from ovaries of different weights . . . . .	86
5. 17 $\beta$ -Hydroxysteroid dehydrogenase activity per 100 mg of incubation tissue from testes of different weights . . . . .	87
6. Effect of ovarian weight on the specific activity of 17 $\beta$ -hydroxysteroid dehydrogenase. . . . .	89
7. Effect of testicular weight on the specific activity of 17 $\beta$ -hydroxysteroid dehydrogenase . . . . .	89
8. Effect of ovarian weight on the total activity of 17 $\beta$ -hydroxysteroid dehydrogenase . . . . .	90
9. Effect of testicular weight on the total activity of 17 $\beta$ -hydroxysteroid dehydrogenase . . . . .	90
10. Flow sheet of the isolation and identification of testosterone formed from androstenedione substrate as described in the text . . . . .	92

## PART A

# CHARACTERIZATION AND IDENTIFICATION OF SOME POLAR PRODUCTS OF IN VITRO PREGN-5-ENE-3 $\beta$ ,17 $\alpha$ -DIOL-20-ONE (17 $\alpha$ -HYDROXYPREGNENOLONE) AND PREGN-4-ENE 17 $\alpha$ -OL-3,20-DIONE (17 $\alpha$ -HYDROXYPROGESTERONE) METABOLISM BY WILSON'S PHALAROPE OVARIAN TISSUE

### I. INTRODUCTION

The family Phalaropidae consists of three species of small shore-birds, the red, northern and Wilson's phalaropes. All three species show a considerable degree of sex reversal in comparison to normal passerine, anserine and upland game birds in which the male is the dominant sex.

The female phalaropes have the more brilliant nuptial plumage and are more aggressive in courtship and pair formation than the males. It is suggested that sex hormones might be related to the development of the breeding plumage (12). Recent investigations by Johns (54) have shown that when phalaropes are partially plucked in the autumn, the new feathers that grow in the plucked area are highly colored as in breeding females if the birds are treated with the male sex hormone, but not when treated with the female sex hormone.

Höhn and Cheng (49) reported that the testosterone content of the ovaries exceeds that of the testes in breeding phalaropes. However, only the male incubates the eggs, cares for the young and develops the incubation patch. Pfeiffer and Johns (53) demonstrated that male sex hormone (testosterone) and prolactin are required for the formation of a

brood patch. The reason that female phalaropes do not form brood patches is apparently due to a deficiency of prolactin, although blood levels of testosterone also may be low at this time (80).

The prenuptial molt occurs in the early spring and egg laying from May to July. Presumably testosterone secretion by the ovaries exceeds that of the testes during the time of the prenuptial molt. On the basis of the assumption concerning a high testosterone secretion by the ovary in the early spring and a decreasing testosterone production when the reproductive season approaches, the secretion of androgen by the ovaries might follow curve 1 in Figure 1. On the other hand, the secretion of androgen by the testes might follow curve 2 as indicated in Figure 1 since the male apparently does not produce sufficient androgen in early spring to stimulate the development of the bright female type breeding plumage. It is the purpose of the present experiments (Part B) to investigate this hypothesis by measuring the  $17\beta$ -hydroxysteroid dehydrogenase activity present in the gonads of phalarope during the breeding season.

Recent studies have shown that the sequence of reactions of pregn-5-ene- $3\beta$ -ol-20-one (pregnenolone)  $\rightarrow$  pregn-4-ene-3,20-dione (progesterone)  $\rightarrow$   $17\alpha$ -hydroxyprogesterone  $\rightarrow$  androst-4-ene-3,17-dione (androstenedione)  $\rightarrow$  androst-4-ene- $17\beta$ -ol-3-one (testosterone) exist in all organs which synthesize steroid hormones (Figure 2) (62,93,96). An alternate pathway of conversion pregnenolone to testosterone via  $17\alpha$ -hydroxypregnenolone, androst-5-ene- $3\beta$ -ol-17-one (dehydroepiandrosterone), and androstenedione has been reported for mammalian endocrine tissue as well (Figure 2) (57,107). The placenta and ovary can further convert




Figure 1 Seasonal change in androgen secretion by phalarope gonadal tissues (hypothetical curves).

- curve 1. androgen secretion in ovarian tissue.
- - - - - curve 2. androgen secretion in testicular tissue.



androgens to estra-1,3,5-triene-3-ol-17-one (estrone) and estra-1,3,5-triene-3,17 $\beta$ -diol (17 $\beta$ -estradiol) (6,112,83).

It has been well demonstrated by Fevold and Eik-Nes (34,35) that avian testicular tissue is capable of synthesizing both testosterone and androstenedione from progesterone in vitro via a pathway similar to that found for homogenated mammalian tissue (91,83,93). However, there is a major difference in progesterone metabolism between avian and mammalian testicular tissue in the extent of 20-ketone reduction (35). On the other hand, the biosynthesis of some non-phenolic polar steroids and estrogens by Wilson's phalarope ovarian tissue has not been investigated. It is the purpose of these experiments (Part A) to investigate the in vitro biosynthesis of some polar non-phenolic steroids and estrogens from 17 $\alpha$ -hydroxypregnenolone and 17 $\alpha$ -hydroxyprogesterone by ovarian tissue of Wilson's phalarope.

## II. HISTORICAL REVIEW

### A. Biosynthesis of pregn-4-ene-17 $\alpha$ ,20 $\alpha$ -diol-3-one and pregn-4-ene-17 $\alpha$ ,20 $\beta$ -diol-3-one.

Early in 1951, pregn-4-ene-17 $\alpha$ ,20 $\beta$ -diol-3-one (17 $\alpha$ ,20 $\beta$ -dihydroxyprogesterone) was first detected as a metabolite of 17 $\alpha$ -hydroxyprogesterone by perfused bovine adrenals (48). After several years, Lynn and Brown (66) isolated the same steroid from testicular tissue incubated with progesterone.

Evidence of the formation of both steroid glycols (20 $\alpha$  and 20 $\beta$  form) from 17 $\alpha$ -hydroxyprogesterone by ovarian tissue was first demonstrated by Sandor and Lanthier (90). During the same year, these two steroid glycols were found by German biochemists as the intermediates of progesterone by perfused bovine (76) and porcine adrenals (77). Human fetal testicular tissue is also capable of producing both of these 20-ketone reduction products of 17 $\alpha$ -hydroxyprogesterone (1).

It is of interest to note that these two steroid glycols can be formed by non-mammalian vertebrates as well. The 20 $\beta$ -hydroxy steroid has been identified in the blood of Pacific salmon (Oncorhynchus nerka) by Idler and his coworkers in 1960 (52). Furthermore, both 20-hydroxy epimers of reduced 17 $\alpha$ -hydroxyprogesterone were isolated from homogenates of testes of English sparrow (Passer domesticus) incubated with progesterone-4-<sup>14</sup>C (34).

The formation of  $\alpha$ -isomer or both of these steroid glycols has been reported by other investigators: the  $\alpha$ -isomer by bovine adrenal and ovary incubated with 17 $\alpha$ -hydroxyprogesterone (63); the 20 $\alpha$ -isomer

from progesterone by human minced ovary (107); and both isomers from human testicular tumor tissue after incubation with either progesterone or  $17\alpha$ -hydroxyprogesterone (25).

C-20 reductase activity acting on various substrates has been demonstrated in all steroid producing glands (115). As far as biological function of the  $20\alpha$  and  $20\beta$  reduced  $17\alpha$ -hydroxyprogesterone is concerned, very few reports have been published. Fevold and Eik-Nes (36) reported that the presence of 1.0 micromole of unlabeled pregn-4-ene- $17\alpha,20\alpha$ -diol-3-one in the testicular tissue of English sparrow incubation medium, progesterone used as substrate, caused a 60% inhibition of the formation of testosterone and 30% decrease in the androstenedione accumulation. It is suggested that this steroid might inhibit the  $17\alpha$ -hydroxyprogesterone side chain cleaving enzyme (C-17,20-desmolase). It is also suggested that these two C-20 epimers of reduced  $17\alpha$ -hydroxyprogesterone cannot be the intermediates in the pathway of formation of androstenedione or testosterone from  $17\alpha$ -hydroxyprogesterone since they are the end metabolites in bird's testicular tissue (33).

#### B. Biosynthesis of estrogens.

The three main estrogens in the human are estrone,  $17\beta$ -estradiol and estra-1,3,5-triene-3,16 $\alpha,17\beta$ -triol (estriol).  $17\beta$ -Estradiol is the most potent estrogen in the Allen-Doisy test (2). The ovary is considered as the main site of estrogens formation under normal physiological conditions. During pregnancy placental estrogen secretion is a 100-1000 times greater than that of the ovary. Recently it has been shown that

testes, adrenal cortices (7) and corpora lutea (51) also take part in the synthesis of estrogens.

The estrogenic hormone was first demonstrated by Doisy and Allen in 1923. A vast amount of work in isolation of estrone and  $17\beta$ -estradiol eventually culminated in 1929-1930 (19,67,23,20,24).

Numerous studies have shown that estrogens may arise from acetate, cholesterol, progesterone and androgens. Heard and his co-workers (46,47) were the first to study the biogenesis of estrogens from acetate in vivo. They demonstrated that acetate- $1^{14}\text{C}$  could serve as an efficient precursor of estrone in the pregnant mare. In later years, in vitro studies have shown that estrone and  $17\beta$ -estradiol are produced from  $^{14}\text{C}$ -labeled acetate in the ovaries of human and dog and in the testes of human, dog and cat (16). Labeled pregnenolone may act as precursor to estrone and  $17\beta$ -estradiol in the ovaries of the human and the pig (21). Estrogens can also arise from progesterone in the ovaries of many species (16).

There are two pathways for the production of testosterone from pregnenolone. The first is  $\Delta^4$ -pathway which consists of the formation of testosterone via progesterone,  $17\alpha$ -hydroxyprogesterone and androstenedione. The other  $\Delta^5$ -pathway involves  $17\alpha$ -hydroxypregnenolone, dehydroepiandrosterone and androstenedione.

The  $\Delta^4$ -route was first reported by Slaunwhite and Samuels (93) in testicular tissue and has been verified by several workers (28,92,29). Solmon et al. (96) also suggested that a  $\Delta^4$ -pathway exists from progesterone to estrogens in bovine ovarian tissue. The  $\Delta^5$ -pathway has been reported by several workers to occur in dog (28), rabbit (44) and

bovine tissue (57). In addition, androst-5-ene-3 $\beta$ ,17 $\beta$ -diol (androstenediol) has been postulated as an intermediate in the testosterone biosynthesis in the  $\Delta^5$ -pathway (82,41,29,94). Ellis and Berliner (29) demonstrated that pregnenolone is biotransformed into testosterone in mouse testes through an alternative pathway which involves 17 $\alpha$ -hydroxypregnenolone, dehydroepiandrosterone and androstenediol as intermediates. Rosner et al. (82) reported that after equal concentrations of dehydroepiandrosterone-7- $\alpha$ - $^3\text{H}$  and 17 $\alpha$ -hydroxyprogesterone-4- $^{14}\text{C}$  were incubated with rabbit testicular tissue, the ratio of  $^3\text{H}$  to  $^{14}\text{C}$  was higher in the enzymatically synthesized testosterone than in androstenedione, indicating that dehydroepiandrosterone could form testosterone without going through androstenedione step. However, it is difficult to interpret the experimental results only by the  $^3\text{H}/^{14}\text{C}$  ratio of metabolites obtained from the double labeled substrates without considering endogenous steroids level present in the tissue. The conversion of androstenediol into testosterone has been observed in bacterial preparation (104), and homogenates of human placenta and adrenocortical tumor tissue (9,10). It is suggested that androstenedione is not an obligatory intermediate in testosterone biosynthesis. A generalized scheme of androgen biosynthesis is presented in Figure 2.

In 1936, Fisher expressed the opinion that testosterone could be converted to natural estrogens by removal of the angular methyl group at C-10 (16). During later years, many biochemists demonstrated the conversion of either androstenedione or testosterone into estrogens in the human placenta, ovaries, testes, adrenal cortices, and corpora lutea (21).

An important discovery in elucidating the estrogen biosynthetic pathway was proved by Meyer (73). He isolated and identified 19-hydroxy-4-androstene-3,17-dione(19-hydroxy-androstenedione) from a homogenate of bovine adrenals incubated with androstenedione and dehydroepiandrosterone. He then concluded that 19-hydroxyl compounds are formed before aromatization occurs. Additional evidence for the role of the 19-hydroxyl derivatives as intermediates in estrogens synthesis was provided by the studies of Longchamp et al. (65). Further work in this field was considerably facilitated by Ryan (84). He discovered that the human placenta contains an enzyme system which is capable of aromatizing androstenedione to estrone in yields of 50-70% when the proper enzyme-substrate ratios were observed. The aromatizing enzyme is localized in the microsomal fraction and requires oxygen and NADPH whereas NADH is ineffective. Hayano et al. (45) obtained the same yield of estrone from 19-oxo-androst-4-ene-3,17-dione(19-oxo-androstenedione) as from 19-hydroxy-androstenedione after incubation with placental microsomes. Therefore, 19-oxo-androstenedione is also a possible intermediate in the pathway of aromatization. An important contribution to the aromatizing mechanism in the estrogens biosynthesis was observed by Breuer and Grill who incubated testosterone, androstenedione and 19-hydroxyandrostenedione with microsomes from human placenta in the presence of NADPH and detected formadehyde and estrogens in the incubation medium from these substrates. The molar ratio of the two products was close to 1 (16).

Until recently,  $\Delta^4$ -3-keto-C<sub>19</sub>-steroids were supposed to be obligatory intermediate precursors of estrogens biosynthesis. The well known




Figure 2 Biosynthesis of androgens

aromatization of dehydroepiandrosterone to estrogens has been explained by the reaction sequence: dehydroepiandrosterone $\longrightarrow$  androstenedione or testosterone $\longrightarrow$  19-hydroxyandrostenedione or 19-hydroxytestosterone $\longrightarrow$  estrogens. However, the ability of 19-hydroxydehydroepiandrosterone to be aromatized by placental microsomes has been proved by Wilcox and Engel (111). This fact was confirmed by the experiments of Starka and Stastny (98) who observed that the aromatization of 19-hydroxydehydroepiandrosterone by placental cytoplasmatic and microsomal cell fraction in vitro exceeded not only the aromatization rates of dehydroepiandrosterone or androstenedione but even that 19-hydroxyandrostenedione. Moreover, 19-hydroxydehydroepiandrosterone was identified in the polycystic ovarian tissue incubated with dehydroepiandrosterone (98). This indicates that aromatization of dehydroepiandrosterone may proceed by the pathway via 19-hydroxydehydroepiandrosterone, but with the evidence available it is not possible to deduce whether the conversion of 19-hydroxydehydroepiandrosterone to 19-hydroxyandrostenedione or 19-hydroxytestosterone is an obligatory step in the formation of estrogens from this precursor.

The interconversion of  $17\beta$ -estradiol and estrone is the best-known and well demonstrated reaction in vitro and in vivo under various experimental conditions in a large number of mammals including rats, guinea pigs, rabbits, cattle and human (16,27). The enzyme responsible for this conversion is  $17\beta$ -estradiol dehydrogenase, which has been purified by Langer and Engel (60) from human placenta.

Estriol was first isolated from human pregnancy urine by Marrian in 1930. During the following years, Pincus and coworkers demonstrated



the conversion of estrone and  $17\beta$ -estradiol to estriol in man (16). Engel et al. (32) and Breuer and coworkers (15) discovered that human liver tissue has the function of converting  $17\beta$ -estradiol into estriol. Recently Ryan (85) demonstrated that androst-5-ene- $3\beta,16\alpha$ -diol-17-one ( $16\alpha$ -hydroxydehydroepiandrosterone) can be converted to estriol via  $16\alpha$ -hydroxytestosterone in human placenta. A  $16\alpha$ -hydroxy-nonphenolic compound has also been reported as the precursor of estriol in sow ovary by Kadis (55) and Ryan and Magendantz (88) have isolated  $16\alpha$ -hydroxy-epiandrosterone as an estriol precursor from human blood. The presence of a  $16\alpha$ -hydroxylase enzyme system has been reported in sow ovary (56), in swine adrenals (81) and in human ovary (106). Therefore estriol can be synthesized from  $16\alpha$ -hydroxylated non-phenolic compound without involving estrone and estriol.

A summary of the various possible biosynthetic pathways to estrogens are presented in Figures 2 and 3.

Several other phenolic steroids have been subsequently isolated and identified: estra-1,3,5-triene- $3,16\beta,17\beta$ -triol (16-epiestriol) from human pregnancy urine (69,70); estra-1,3,5-triene- $3,16\alpha$ -diol-17-one ( $16\alpha$ -hydroxyestrobene) in human pregnancy urine (71,72); estra-1,3,5-triene- $3,16\beta$ -diol-17-one ( $16\beta$ -hydroxyestrone) in women's urine (16); 2-methoxy-estra-1,3,5-triene- $3\alpha$ -ol-17-one (2-methoxy-estrone) from human placenta perfusion with  $17\beta$ -estradiol (31,103).

Marrian et al. (71,72) suggested the hypothesis that  $16\alpha$ -hydroxy-estrone and  $16\beta$ -hydroxyestrone are formed from estrone by  $16\alpha$  and  $16\beta$  - hydroxylation and they are intermediate in the "hydration" of estrone to estriol and 16-epiestriol, respectively. This hypothesis was strength-




Figure 3. Biosynthesis of estrogens from C-19 steroids

ened by the finding of estriol in the urine of two persons receiving injection of 16 $\alpha$ -hydroxyestrone (18) and by the isolation of estriol, estra-1,3,5-triene-3,16 $\alpha$ ,17 $\alpha$ -triol(17-epiestriol) and estra-1,3,5-triene-3,16 $\beta$ ,17 $\alpha$ -triol(16,17-epiestriol) from human liver slice incubated with 16 $\alpha$ -hydroxyestrone (16).

Another 16-substituted estrogen which plays an important part in the intermediary metabolism is 16-oxo-17 $\beta$ -estriol. This phenolic steroid was first obtained in human urine after injection of 17 $\beta$ -estradiol-16-<sup>14</sup>C (61) and later it was isolated from pregnancy urine by Marrian (71). King (58) incubated estriol with rat kidney homogenates in the presence of NAD and NADP and isolated 16-oxo-17 $\beta$ -estradiol and 16-epiestriol. After incubation of 16-epiestriol in the same system, 16-oxo-17 $\beta$ -estradiol and estriol were detected. Therefore, he suggested that the introduction of 16-keto group most likely proceeds by way of 16 $\alpha$ -hydroxylation and the action of a 16-dehydrogenase.

Although 16-oxo-estrone was suspected as an oxidation product of estriol (68), it is not an end product of estrogen metabolism (99,100). Estriol and 16-epiestriol were detected in the urine of a man who had received an injection of 16-oxo-estrone (101). Breuer et al (14) reported that 16-oxo-estrone is a key substance in the metabolism of the 16-substituted estrogens. He found that metabolites after incubation of 16-oxo-estrone with human liver slice were 16 $\alpha$ -hydroxyestrone, 16 $\beta$ -hydroxyestrone, 16-oxo-17 $\beta$ -estradiol, estriol, 16-epiestriol, 17-epiestriol and 16,17-epiestriol. However, little information concerning the formation of the 16-oxogenated estrogens by gonadal tissue is available. The interrelations of 16-oxo-estrone, 16-oxo-17 $\beta$ -estradiol and

other 16 and 17 substituted phenolic estrogens are presented in Figure 4.

The metabolic reactions involve a wide variety of transformations such as introduction of hydroxy groups, reversible oxidation-reduction of hydroxyl and carbonyl groups and methylation. In general, C-2, C-6, C-16 of the estrogens appear to be the most prominent metabolic transformation positions (31,15,72). More detailed interrelationship of metabolism of estrogens will not be discussed here.




Figure 4. Interrelationship of estrone and 17β-estradiol with 16 and 17 substituted phenolic estrogens.

### III. EXPERIMENTAL MATERIALS AND PROCEDURES

#### A. Experimental animals.

Wilson's phalarope was selected as the experimental animal since it shows a partial sex reversal behavior. The birds were obtained in Western Montana during the first two weeks of May. Within ten minutes after the birds were shot, the gonads were removed, weighed, and frozen in liquid nitrogen.

#### B. Chemicals.

1. 17 $\alpha$ -Hydroxypregnenolone-7 $\alpha$ -<sup>3</sup>H (Mann S 4890), specific activity 100 mc/mmole.
2. 17 $\alpha$ -Hydroxyprogesterone-4-<sup>14</sup>C (Nuclear England Corp., Lot No. 134-204-23a), specific activity 36.2 mc/mmole.
3. Estrone-6,7-<sup>3</sup>H (TRA, 126, Batch 3, Nuclear Chicago), specific activity 500 mc/mmole.
4. 17 $\beta$ -Estradiol-4-<sup>14</sup>C (Batch 2, CFA 320, Nuclear Chicago), specific activity 31.8 mc/mmole.
5. 20 $\alpha$ -Reduced form of 17 $\alpha$ -hydroxypregnenolone-7 $\alpha$ -<sup>3</sup>H (specific activity as number 1) was prepared by reduction with LiAlH<sub>4</sub> in benzene and ether solvents (personal communication, J. W. Hinman, The Upjohn Co., Kalamazoo, Mich.)

All radioactive standard steroids were purified by paper chromatography in the benzene/formamide system prior to use.

#### 6. Cofactors and additives

- a. Triphosphopyridine nucleotide (TPN), Lot. No. 16-B-7002, and diphosphopyridine nucleotide (DPN), Lot No. 15-B-7260 were

obtained from the Sigma Chemical Company and used without further purification.

b. Adenosine triphosphate (ATP) 99% pure, control No. 6211 was obtained from Nutritional Biochemical Corporation.

c. Sodium fumarate (Fu 15684) was made by C. F. Boehringer and Soehne GmbH Mannheim Company in Germany.

d. Nicotinamide was procured from Matheson, Coleman, and Bell Company.

7. Buffer. Krebs-Ringer phosphate buffer was prepared as described by Umbreit et al. (105).

8. Standard steroid solutions. Steroid solutions were prepared by dissolving weighed quantities of crystalline steroids in redistilled ethanol and were stored at 4°C. The concentrations of solutions of  $\Delta^4$ -3-keto steroids were determined by their ultraviolet absorbance at 240 m $\mu$ .

9. Solvents. All solvents were spectral grade or were redistilled prior to use.

10. 1,2-Dihydroxypropane (propylene glycol) was obtained from Matheson, Coleman and Bell Company (Lot N. 2493) and was used without further purification.

11. Chromium trioxide (CrO<sub>3</sub>), Lot No. 2576, Mallinckrodt Chemical works was stored in a desiccator.

12. Pyridine with a Lot No. 7180 was obtained from the same company as that of CrO<sub>3</sub> and was vacuum redistilled and stored in a desiccator.

13. A.C.S. reagent Code 1002 acetic anhydride was purchased from Allied Chemical Company and stored in a desiccator after vacuum distillation.

14. Acetic acid. Allied Chemical glacial acetic acid (A.S.C. reagent Code 1019) was vacuum redistilled over acetic anhydride and stored in a desiccator.

15. Dimethyl sulfate with Lot No. p 328 was obtained from Easterman Organic Chemicals and redistilled before use.

16. Glucose-6-phosphate dehydrogenase was purchased from Cal-Biochemical Company, with Lot No. 64891, 140 Eu/mg.

17. Scintillation mixture. This solution was prepared by dissolving 4 gm of 2,5-diphenyloxazole (PPO) and 50 mg of 1,4-bis-2-(5-phenyloazolyl)-benzene (POPOP) in one liter of toluene and was stored in a brown bottle.

18. Silica gel. Silica gel G, No. 7731, acc. to Stahl from E. Merck AG. Darmstad (Germany) Company was used for thin layer chromatography. Silica gel (No. 7734) from the same company as above with mesh size 0.05-0.20 mm was used for column chromatography.

19. Chromatography paper. Whatman No. 1 filter paper (46x57 cms) was used for chromatographic separation.

20. Nitrogen. Bottled water-pumped nitrogen was obtained from the Industrial Air Products Company and filtered through glass wool prior to use.

21. Thin layer chromatography plate. Thin layer chromatography was done on glass plates coated with silica gel G. Fifty milliliters



water was added to 25 gm silica gel G mixed with luminescent phosphor (Du pont 609), and the slurry was spread on various size glass plates (20x20, 8x20, 5x20 cms) at a thickness of 0.2 mm. After half an hour, the plates were heated at 110°C for 1.5 hours and placed in a desiccator (4).

22. N,N-dimethyl formamide, Matheson, Coleman, and Bell Co., SG 5974.
23. Bis-(trimethylsilyl)-acetamide, Chemical Co., Inc. 071071.
24. Trimethylchlorosilane(CH<sub>3</sub>SiCl<sub>3</sub>), Pierce Chemical Company, stock No. 885 304.

#### C. Equipment.

1. Shaking incubator - A research Specialties Model 2156 Constant temperature shaking water bath was used for the incubations.
2. Strip counter - A Model RSC paper strip and thin-layer plate gas-flow counter designed by Atomic Accessories, Inc., was used to locate radioactivity on paper and thin-layer chromatograms.
3. Scintillation counter - A Liquid Scintillation Spectrometer (Nuclear Chicago Model No. 812830) was used to determine <sup>3</sup>H and <sup>14</sup>C quantitatively (106).
4. Spectrophotometers - Beckman Model DU spectrophotometer was used to determine the absorbancy of solutions at various wave lengths.
5. Haines scanner - Ultraviolet absorbing material on paper chromatograms was located by use of a scanning device described by Haines (1950).
6. pH meter - A Corning pH meter Model 12 was used to measure the pH of the buffer solutions.

7. Gas Chromatography apparatus - F and M Scientific Model 402 High Efficiency Gas Chromatograph equipped with dual flame ionization detectors was employed for steroid identification to analyze steroids.

8. Autoclave - The glassware for incubations was sterilized in an American Sterilizer (patent number 2470776) designed by Erie Company, Pennsylvania.

9. Centrifuge - A Model No. 76344 H centrifuge manufactured by International Equipment Co. was used to centrifuge the mixtures.

#### D. Procedures.

##### 1. Paper chromatography

Two centimeter strips of Whatman No. 1 filter paper were impregnated with formamide as the stationary phase, loaded with the substance and the mobile phase added last. The choice of the solvent systems was according to Zaffaroni-type systems (113,114). The chromatograms were allowed to develop in a sealed glass tank, pre-saturated with developing solvents, with descending flow technique.

##### 2. Drying process

The aliquots of samples were evaporated to dryness under a stream of nitrogen gas in a constant temperature water bath at 40°C. The residues were rinsed with absolute ethanol.

##### 3. Substrate preparations

Fifty-two microcuries of 17 $\alpha$ -hydroxypregnenolone-7 $\alpha$ -<sup>3</sup>H, 0.43 mg of non-radioactive 17 $\alpha$ -hydroxypregnenolone, 19.5  $\mu$ c of 17 $\alpha$ -hydroxyprogesterone-4-<sup>14</sup>C and 0.25 mg of non-radioactive 17 $\alpha$ -hydroxyprogesterone were dissolved in 2.6 ml ethanol propylene glycol(1:1). The final con-

centrations were approximately 0.05  $\mu$ mole and 2  $\mu$ c of 17 $\alpha$ -hydroxypregnenolone and 0.05  $\mu$ mole plus 0.75  $\mu$ c of 17 $\alpha$ -hydroxyprogesterone per 10 ml of ethanol:propylene glycol(1:1). The tube containing substrates was stored in a freezer until used.

#### 4. Tissue preparation

Previously frozen ovarian tissue was thawed and placed in a glass homogenizer containing 20 ml Krebs-Ringer phosphate buffer pH 7.35 and homogenized with a Ten-Broek tissue grinder at 0°C. (Table 1).

Concentration of cofactors in the buffer were 40 mM nicotinamide; 0.4 mM DPN, ATP, and TPN; 0.1 mM sodium fumarate; and 1 mg/ml of both D-glucose-6-phosphate and  $\beta$ -D-glucose. The tissue concentration was 104 mg per ml.

#### 5. Preparation of incubation flasks

All glassware used in the incubations was sterilized in an autoclave prior to use to prevent microbiological transformations of steroid molecules. Glass stoppered or cork stoppered 25 ml Erlenmeyer flasks were used as incubation vessels.

Two tenth ml of substrates were added to each incubation flask and ethanol was evaporated. Two ml of homogenate and glucose-6-phosphate dehydrogenase were placed into the incubation flasks. Blank incubation flasks were prepared in the same manner except the tissue homogenate was replaced by Krebs-Ringer phosphate buffer containing cofactors. The flasks were gassed for one minute with 95% O<sub>2</sub>-5% CO<sub>2</sub> immediately after the addition of the homogenate and tightly stoppered.

#### 6. Incubation

Table 1

Phalarope ovaries used for incubation

<u>Bird No.</u>	<u>Date collected</u>	<u>Weight(mg)</u>
66-4	5-16-66	225.0
66-9	"	195.0
66-10	"	144.8
66-17	"	446.0
66-21	"	136.4
66-31	"	242.0
66-32	"	220.0
65-6	5-7-65	130.8
65-41	6-21-65	182.8
65-65	6-21-65	158.4
65-62		

Total wt. 2081.2 mg

Remarks: Each incubation flask contained about 208.1 mg  
homogenized tissue.

Each flask was placed in the constant temperature shaking water bath and incubated at  $41^{\circ}\text{C}$  for three hours. The reaction was stopped by adding 5.0 ml diethyl ether:ethyl acetate (4:1, v/v), mixing thoroughly and freezing at  $-20^{\circ}\text{C}$ .

## 7. Extraction

a. The incubation media were thawed, transferred into citric acid tubes and the incubation flasks were rinsed with 3.0 ml glass-redistilled water. The resulting 5.0 ml aqueous phase was extracted with four 10.0 ml volumes of ethyl ether:ethyl acetate (4:1, v/v). The extraction tubes were centrifuged for ten minutes at 2500 rpm after each extraction to separate emulsions. The four volumes of organic extract were combined and evaporated to dryness.

b. One tenth microcurie of estrone-6,7- $^3\text{H}$ , 0.04  $\mu\text{c}$  of estradiol-4- $^{14}\text{C}$  and 0.01  $\mu\text{c}$  of  $20\alpha$ -reduced form of  $17\alpha$ -hydroxypregnolone-7- $^3\text{H}$  were added in 5 ml of water to each of two citric acid tubes. Extraction of these standards was carried out at the same time and in the same manner as were the incubation samples. The results from these extractions were used for the calculation of the percent recovery of the added compounds.

## 8. Product purification, isolation and identification

a. Separation of neutral steroids from phenolic steroids

Separation of the phenolic and non-phenolic steroid was accomplished by partitioning the extracts between 1.0 N NaOH and toluene (30).

The neutral steroid fraction was chromatographed on paper in the

heptane/formamide system. The chromatograms were allowed to run for one hour after the mobile phase had reached the end of the strips and were then removed from the tank. After the heptane was evaporated from the paper, the strips were further developed in the heptane:benzene(1:1)/formamide system to front. Fifty micrograms each of authentic testosterone, androstenedione and progesterone were chromatographed on a separate strip with each sample chromatogram.

The phenolic steroids were chromatographed in the benzene/formamide system to front. Fifty micrograms each of authentic estrone and  $17\beta$ -estradiol were chromatographed simultaneously with each chromatogram of samples. The ultraviolet absorbing compounds located on the dry chromatograms were visualized by means of the Haines scanner and the non-radioactive standard estrogens were detected by running Barton's reaction (8) on the dried standard strip. The radioactive steroids on the chromatogram were located by scanning on a strip counter.

Areas of the chromatograms containing radioactive metabolites were eluted with methanol. Like fractions were pooled and evaporated to dryness for further identification.

b. Further paper chromatographic separations were employed in the following systems:

- |                         |                                      |
|-------------------------|--------------------------------------|
| 1. benzene/formamide    | 2. heptane:benzene(1:1)/formamide    |
| 3. heptane/formamide    | 4. chloroform:benzene(1:1)/formamide |
| 5. chloroform/formamide | 6. toluene/propylene glycol          |

Each isolated substance was repeatedly chromatographed in these systems to establish homogeneity.

c. Acetylation

After the separation of steroids appeared to be complete, acetylation were performed. Two tenth ml of pyridine:acetic anhydride (4:1 v/v) were placed in the tube containing the unknown metabolite. The tube was tightly stoppered and placed in a dark hood overnight (8-16 hours). The reaction was stopped by the addition of one ml of absolute ethanol. The ethanol, pyridine and acetic anhydride were evaporated. The acetate derivatives of unknown and standard steroids were applied to paper strips and the chromatogram developed in several systems as mentioned above (33).

d. Saponification

Since the amount of metabolites available was small, the acetate derivatives were saponified to regain the original compound. Saponification was performed by dissolving the acetate derivatives in 0.5 ml ethanol to which 0.5 ml of 2.5% sodium carbonate was added. The reaction was allowed to proceed at room temperature overnight. At the end of this period, the ethanol was evaporated; the solution diluted to 5 ml with water; and the saponified material and remaining ester were extracted with five equal volumes of ethylacetate. The free and esterified compounds were separated by paper chromatography in appropriate systems (33).

e. Oxidation

The free steroids obtained by saponification were identified further by oxidation with 0.2 ml of a saturated solution of chromium trioxide( $\text{CrO}_3$ ) in glacial acetic acid. After thirty minutes of reaction

5.0 ml of deionized water were added to tubes and the aqueous solution was extracted immediately with 5.0 ml ethyl acetate. The extraction was repeated three times. The extraction volumes were combined and evaporated to dryness (33).

f. Column chromatography

Phenolic metabolites were purified by chromatography on silica gel columns, eluted sequentially with dichloromethane ( $\text{CH}_2\text{Cl}_2$ ) containing 0%, 2%, 5%, 10% and 20% acetone. A total of 15 ml of each solvent mixture was added to the column and the effluent collected in three 5.0 ml aliquots, labeled as A, B and C. The standard estrogens eluted from the column were determined by Kober's reaction, and absorbance values were determined by using Allen's correction (3,102,17).

g. Methylation

Methylation of steroids was performed according to Attal's method (4). Six ml of 1 N NaOH were added to samples, followed by the addition of 5.0 ml of 4.5% (w/v) boric acid in water. The mixture was kept at 40°C for 5 minutes; 0.5 ml of dimethyl sulfate was added and the mixture shaken vigorously and left overnight at 40°C. Two and half ml of 20% (w/v) aqueous sodium hydroxide was added and the mixture extracted with 5 ml n-hexane three times. The combined hexane extracts were washed with 2 ml distilled water and evaporated to dryness.

h. Thin-layer chromatography

Thin-layer chromatography was performed according to the method of Neher (79). The silica gel thin-layer chromatography plates were heated at 110°C for one hour prior to use. After the samples were



loaded, the plates were placed in a sealed glass tank containing the appropriate developing solvents and ascending developing technique was employed (64,97,4).

The radioactive steroids on the plates were located by counting radioactivity on a thin-layer counter. The non-radioactive estrogens on the plates were detected by exposing the plates to iodine vapor.

i. Elution technique from thin-layer plates

The silica gel containing the steroids of interest was scraped off the plate 0.5 cm below and 0.5 cm above the area corresponding to radioactive area. The removed silica gel was extracted with proper solvents (4).

j. Gas chromatography

Suitable derivatives of steroids were made for gas chromatographic analysis. Bis-trimethyl silyl ether derivative of unknowns was formed by adding 25  $\mu$ l of reagent mixture (1.6 ml N,N-dimethyl formamide, 0.4 ml trimethyl-chlorosilane and 0.3 ml Bis-(trimethylsilyl)-acetamide to the unknowns containing 10 microgram of cholestane (59).

Analysis of the samples and the blanks were performed by using either a 3' mm I.D. x 4' glass column coated with 3.8% SE-30 or a 3' mm I.D. x 6' glass column coated with 2.0% XE-60 on Model 402 High Efficiency Gas Chromatograph.

#### IV. RESULTS

##### A. Identification of metabolites $X_1$ and $X_2$

Figure 5 is the tracing of the initial paper chromatogram of neutral metabolites isolated from the incubation media.  $X_1$  and  $X_2$  were isolated from the most polar fraction of the non-phenolic metabolites (Figure 5 area #1). Further purification and identification of unknowns are presented in Figures 6 and 7. The chromatographic evidence supporting the identities of  $X_1$  and  $X_2$  is shown in Tables 2 and 3.

Both  $X_1$  and  $X_2$  have an ultra-violet absorption maximum around 240 m $\mu$ . Acetylation of  $X_1$  produced a monoacetate derivative of lower polarity. The monoacetate derivative of  $X_1$  had the same mobility as the authentic 20 $\alpha$ -acetate derivative of pregn-4-ene-17 $\alpha$ ,20 $\alpha$ -dihydroxy-3-one (17 $\alpha$ ,20 $\alpha$ -dihydroxyprogesterone) in three different paper chromatographic systems (Table 2). The mobility of  $X_2$  was slightly less polar than  $X_1$ . It also formed a monoacetate derivative on acetylation and had the same chromatographic  $R_f$  values as those of the authentic 20 $\beta$ -acetate derivative of pregn-4-ene-17 $\alpha$ ,20 $\beta$ -diol-3-one (17 $\alpha$ ,20 $\beta$ -dihydroxyprogesterone) in several different paper chromatographic systems (Table 3).

Oxidation of  $X_1$  and  $X_2$ , obtained from the saponified acetate derivatives, yielded from each a major product with a chromatographic mobility identical to standard androstenedione and a minor product of  $R_f$  value identical to that of 17 $\alpha$ -hydroxyprogesterone (Tables 2 and 3).

$^3\text{H}/^{14}\text{C}$  Ratios of initial substrates and neutral metabolites  $X_1$  and  $X_2$  were listed in Table 4. Both unknowns contained tritium and carbon-14 label. However, the ratios were less than that of the substrates.




Figure 5. Tracing of the first chromatographic separation of radioactive neutral metabolites isolated from incubations of phalarope ovarian tissues cell-free homogenate with  $17\alpha$ -hydroxypregnenolone- $7\alpha$ - $^3\text{H}$  and  $17\alpha$ -hydroxyprogesterone- $4$ - $^{14}\text{C}$  substrates.

T = authentic testosterone

A = authentic androstenedione

P = authentic progesterone





Figure 6. Purification of neutral steroids in the benzene/formamide system by paper chromatography.

O. = Origin

● = ultra-violet positive steroids

Figure 7. Procedure used for isolation and identification of X<sub>1</sub> and X<sub>2</sub>



\*  
 PC : paper chromatography  
 TLC: thin layer chromatography

Table 2 Chromatographic identification of X<sub>1</sub>

Paper Chromatographic System	Prior Treatment	R <sub>f</sub> values	
		X <sub>1</sub>	Authentic Standard Pregn-4-ene-17 $\alpha$ ,20 $\alpha$ - diol-3-one
heptane:benzene (1:1)/formamide 8 hrs. overrun	none	4.7-12.5* (8.6)	5.0-12.9* (8.8)
heptane:benzene (1:1)/formamide	Ac	0.32	0.32
heptane:benzene (1:1)/formamide 2 hrs. overrun	Ac	23.2-30.0* (26.5)	24.0-27.2* (26.6)
benzene/formamide	Ac	0.73	0.73
heptane/formamide 4 hrs. overrun	Ac	1.5-6.8* (3.7)	3.0-4.2* (3.6)
heptane:benzene (1:1)/formamide 2 hrs. overrun	Sa	2.7-4.5* (3.6) 25.0-31.5* (28.1)	2.5-4.1* (3.6) 26.5-31.0* (28.3)
heptane:benzene (1:1)/formamide	Ox	0.14** 0.47***	0.15** 0.47***
benzene/formamide	Ox	0.53** 0.73***	0.54** 0.78***
chloroform:acetone (50:50 v/v)****	Sa	0.44	0.44

\*=mobility from origin(cm)

\*\*=mobility similar to 17 $\alpha$ -hydroxyprogesterone in all two systems.

\*\*\*=mobility similar to androstenedione in all two systems.

\*\*\*\*=thin-layer chromatography.

Ac=acetylated.

Ox=oxidized.

Sa=saponified.

Table 3. Chromatographic identification of X<sub>2</sub>

Paper Chromatographic system	Prior Treatment	R <sub>f</sub> values	
		X <sub>2</sub>	Authentic Standard pregn-4-ene-17 $\alpha$ ,20 $\beta$ - diol-3-one
heptane:benzene (1:1)/formamide 8 hrs. overrun	none	9.6-15.0* (11.7)	10.0-12.9* (11.5)
heptane:benzene (1:1)/formamide	Ac	0.32	0.31
heptane:benzene (1:1)/formamide 2 hrs. overrun	Ac	24.6-32.0* (27.9)	25.8-29.3* (27.6)
benzene/formamide	Ac	0.73	0.73
heptane/formamide 4 hrs. overrun	Ac	2.4-6.6* (4.2)	2.9-4.9* (3.9)
heptane:benzene (1:1)/formamide 2 hrs. overrun	Sa	3.0-6.5* (4.2) 24.0-31.0* (27.0)	3.5-4.6* (4.1) 24.7-28.7 (26.8)
heptane:benzene (1:1)/formamide	Ox	0.17** 0.54***	0.17** 0.54***
benzene/formamide	Ox	0.55** 0.78****	0.54** 0.78****
chloroform:acetone (50:50 v/v)****	Sa	0.56	0.56

\*=mobility from origin (cm)

Ac=acetylated.

Ox=oxidized.

Sa=saponified.

\*\*=mobility similar to 17 $\alpha$ -hydroxyprogesterone in both two systems.

\*\*\*=mobility similar to androstenedione in both two systems.

\*\*\*\*=thin layer chromatography.

This means that the formation of unknowns from  $17\alpha$ -hydroxypregnenolone- $7\text{-}^3\text{H}$  was less than that from  $17\alpha$ -hydroxyprogesterone.

The results of paper chromatographic analysis of the parent compound, the acetate derivative and <sup>the</sup>oxidation products of  $X_1$  and  $X_2$  are conclusive evidence that  $X_1$  is pregn- $4$ -ene- $17\alpha$ , $20\alpha$ -diol- $3$ -one, whereas  $X_2$  is pregn- $4$ -ene- $17\alpha$ , $20\beta$ -diol- $3$ -one.

#### B. Partially characterized metabolites

Figure 8 shows the isolation and identification processes used for phenolic steroids. The radiochromatogram scanner tracing of the initial paper chromatographic separation of the phenolic metabolites is presented in Figure 9. Three metabolic fractions, #P<sub>1</sub>, #P<sub>2</sub>, #P<sub>3</sub> were eluted from the chromatograms. #P<sub>2</sub> corresponded to the area of standard  $17\beta$ -estradiol and #P<sub>3</sub> corresponded to the area of standard estrone on the chromatogram. The P<sub>2</sub> and P<sub>3</sub> fractions were further purified through silica gel columns. The effluent patterns of estrone and  $17\beta$ -estradiol through silica gel columns are indicated in Figure 11. Estrone was eluted from the column in fractions 2%B through 5%C acetone in CH<sub>2</sub>Cl<sub>2</sub> whereas  $17\beta$ -estradiol was eluted from 5%C to 20% A acetone in CH<sub>2</sub>Cl<sub>2</sub> fractions. After collecting the eluted estrone and  $17\beta$ -estradiol fractions from the column chromatography of fractions P<sub>2</sub> and P<sub>3</sub>, the methoxy-derivatives were formed.

The thin-layer chromatogram of the methylated products of P<sub>2</sub> and P<sub>3</sub> is shown in Figure 12. The mobility of 3-methoxy- $17\beta$ -estradiol is similar to that of some impurity in the methylation blank. No spot corresponding to authentic 3-methoxy-estrone was found in either P<sub>2</sub> or



Table 4.  $^3\text{H}/^{14}\text{C}$  ratios of initial substrates and neutral metabolites  $X_1$ ,  $X_2$

		$^3\text{H}/^{14}\text{C}$
Substrates	$17\alpha$ -hydroxypregnenolone- $7\alpha$ - $^3\text{H}$	2.535
	$17\alpha$ -hydroxyprogesterone- $4$ - $^{14}\text{C}$	
Metabolites	$X_1$	0.727
	$X_2$	0.456

Table 5. Percent recovery of estrogens in the isolation processes.

Standard Estrogens	Recovery (Initial Extraction)	Recovery (Silica gel Column)	Recovery (Total)
Estrone- $6,7\alpha$ - $^3\text{H}$	59.20%	85.40%	50.10%
$17\beta$ -Estradiol- $4$ - $^{14}\text{C}$	39.15%	58.90%	23.03%






Figure 9 Tracing of the first paper chromatogram of phenolic metabolites isolated from incubation of phalarope ovarian tissue cell-free homogenate with  $17\alpha$ -hydroxypregnenolone- $7\alpha$ - $^3$ H and  $17\alpha$ -hydroxyprogesterone- $4$ - $^{14}$ C in the benzene/formamide system.

$E_1$ =estrone ,  $E_2=17\beta$ estradiol




Figure 10 Tracing of paper chromatogram of phenolic metabolite #P<sub>1</sub> fraction in the chloroform/formamide system.




Figure 11. Effluent patterns of estrone and  $17\beta$ -estradiol in silica gel column with different polarity of eluting solvents.

Remark: 2% A = 2% acetone in  $\text{CH}_2\text{Cl}_2$  fraction A.  
E = Estrone  
E<sub>1</sub>  
E<sub>2</sub> =  $17\beta$ -estradiol




Figure 12 Thin layer chromatogram of methylated estrogen samples in the benzene:methanol(99:1 v/v) system.  
Sample 1 : methylation blank  
" 2 : methoxy-#P<sub>3</sub>  
" 3 : authentic methoxy-estrone  
" 4 : authentic methoxy-17 $\beta$ -estradiol  
" 5 : methoxy-#P<sub>2</sub>

Table 6. Retention time of gas chromatographic analysis of methoxy derivatives of #P<sub>2</sub> and #P<sub>3</sub>

Sample	Temperature °C			R <sup>*</sup> T
	Flash Heater	Flame Detector	Colum Oven	
Methylation TLC Blank	283	263	239	0.417
Standard 3-MeO-E <sub>1</sub>	"	"	"	0.409
Standard 3-MeO-E <sub>2</sub>	"	"	"	0.442
Methoxy- #P <sub>2</sub>	281	259	240	0.405
Methoxy- #P <sub>3</sub>	282	261	240	0.410
Methylation Column Blank	281	259	240	0.407

Colum operating conditions:

H<sub>2</sub> 38.0 ml/min. Range 10 Dual

H<sub>e</sub> 45.0 ml/min. Flame Detector

Air 260 ml/min. 3.8% SE-30 Glass Column 3 mm I.D.x4<sup>8</sup>

R<sub>T</sub> = Relative retention time to cholestane.

Retention time of cholestane is 13.8 ± 0.4 minutes.

repeated. It was found that none of the neutral steroids present in the alkali-insoluble fraction, separated from original P<sub>1</sub>-C, had a mobility similar to that of alkali-soluble P<sub>1</sub>-C fraction. The polarity of the P<sub>1</sub>-C fraction was between 17 $\beta$ -estradiol and 16-oxo-estrone (Table 9). It might be suspected that both P<sub>1</sub>-B and P<sub>1</sub>-C contain some phenolic compounds transformed from estrone or estradiol via hydroxylation or oxidation reaction. Insufficient amount of metabolites precluded the further identification of these compounds.

Table 7.  $R_f$  values of phenolic metabolite #P<sub>1</sub>-A

Chromatographic system	Steroids	$R_f$
Chloroform/formamide (PC)*	#P <sub>1</sub> -A	0.014
	estriol	0.015
	16-epiestriol	0.064
	17-epiestriol	0.050
	17 $\beta$ -estradiol	0.287
	17 $\alpha$ -estradiol	0.291
	16 $\alpha$ -OH-estrone estrone	0.126 0.501
Chloroform:ethanol (90:10) (TLC)*	#P <sub>1</sub> -A	5.47**
	estriol	5.85**
	16-epiestriol	8.0-9.7**
	17-epiestriol	

PC\* = paper chromatography

TLC\* = thin layer chromatography (rechromatographed three times to the solvent front)

\*\* = migration distance from origin(cm)



Table 8.  $R_f$  values of phenolic metabolite #P<sub>1</sub>-B

Paper Chromatographic System	Steroids	$R_f$
Chloroform/formamide	#P <sub>1</sub> -B	0.501
	estriol	0.015
	16 $\alpha$ -OH-estrone	0.126
	17 $\beta$ -estradiol	0.287
	17 $\alpha$ -estradiol	0.291
Chloroform/formamide 4 hrs. overrun	#P <sub>1</sub> -B	4.5-12.5* (8.7)
	16 $\alpha$ -OH-estrone	8.5-12.5* (11.0)
Chloroform/formamide 6 hrs. overrun	#P <sub>1</sub> -B	0.503**
	16 $\alpha$ -OH-estrone	0.604**
	16-oxo-17 $\beta$ -estradiol	0.522**

\* = mobility from origin (cm)

\*\* =  $R_s$  value relative to internal standard pregn-4-ene-17 $\alpha$ ,20 $\alpha$ -diol-3-one

Table 9.  $R_f$  values of phenolic metabolite #P<sub>1</sub>-C

Paper Chromatography System	Steroids	$R_f$
Chloroform/formamide	#P <sub>1</sub> -C	0.505
	17 $\beta$ -estradiol	0.186
Benzene/formamide 4 hrs. overrun	#P <sub>1</sub> -C	0.7-5.0* (2.9)
	estrone	28.7-34.8* (31.7)
	17 $\beta$ -estradiol	10.6-14.1* (12.3)
Chloroform:benzene (1:1)/formamide	#P <sub>1</sub> -C	0.108
	17 $\beta$ -estradiol	0.208
	16 $\alpha$ -OH-estrone	0.054
Chloroform/formamide	#P <sub>1</sub> -C	0.140** 0.276***
	17 $\beta$ -estradiol	0.233
	16-oxo-estradiol	0.049
	16-oxo-estrone	0.116

\* = mobility from origin (cm)  
 \*\* =  $R_f$  value of alkali-insoluble fraction  
 \*\*\* =  $R_f$  value of alkali-soluble fraction

## V. DISCUSSION

The neutral metabolite  $X_1$  was identified as  $17\alpha, 20\alpha$ -dihydroxyprogesterone while  $X_2$  was  $17\alpha, 20\beta$ -dihydroxyprogesterone from chromatographic evidence, but the mobility of  $X_1$  also corresponded to that of pregn-5-ene- $3\beta, 17\alpha, 20\beta$ -triol ( $17\alpha, 20\beta$ -dihydroxypregnenolone) in the heptane:benzene(1:1)/formamide paper chromatographic system. Since  $X_1$  is an ultraviolet positive steroid and forms monoacetate upon acetylation, the possibility of  $X_1$  being  $17\alpha, 20\beta$ -dihydroxypregnenolone was ruled out.

$20\alpha$  and  $20\beta$  reduced isomers of pregn-4-ene- $11\beta$ -ol-3,20-dione ( $11\beta$ -hydroxyprogesterone) cannot be separated from 20 reduced epimers of  $17\alpha$ -hydroxyprogesterone in several paper chromatographic systems (79). Since  $X_1$  and  $X_2$  yielded androstenedione and  $17\alpha$ -hydroxyprogesterone upon oxidation with  $\text{CrO}_3$ /acetic acid, products which would not be formed from  $11\beta, 20\alpha$  ( $20\beta$ )-dihydroxyprogesterone, this possibility is eliminated. Also since the starting substrates contained  $17\alpha$ -hydroxyl groups the products must either still contain this group or be C-19 or C-18 steroids.

$^3\text{H}/^{14}\text{C}$  Ratios of  $X_1$  and  $X_2$  show that both unknowns can be formed from  $17\alpha$ -hydroxypregnenolone- $7\alpha$ - $^3\text{H}$  and  $17\alpha$ -hydroxyprogesterone- $4$ - $^{14}\text{C}$ . However, the  $^3\text{H}/^{14}\text{C}$  ratios of  $X_1$  and  $X_2$  are lower than that of the initial substrates (Table 2). This indicates that the transformation of  $17\alpha$ -hydroxypregnenolone into  $X_1$  and  $X_2$  was less than that of  $17\alpha$ -hydroxyprogesterone. This supports the identification of these unknowns.

The biosynthesis of  $20\alpha$  or  $20\beta$  or both reduced epimers of  $17\alpha$ -hydroxyprogesterone has been reported in a variety of tissues including

human testes (1,66); mouse testes (29); bovine adrenal gland (63,76); human ovarian tissue (90,107) and testes of English sparrow (Passer domesticus) (34). These steroid glycols were also isolated from blood of Pacific salmon (Oncorhynchus nerka) (52). Therefore, 20-hydroxydehydrogenase is generally present in the vertebrate organism. It appears that the present report is the first finding of the formation of these steroid glycols by ovarian tissue. However, it does not provide information as to the quantitative transformation rate of these two compounds from either substrates nor their biological function in the avian system.

There are two possibilities of transformation of  $17\alpha$ -hydroxypregnenolone into  $17\alpha,20\alpha(20\beta)$ -dihydroxyprogesterone. Either oxidation of  $17\alpha$ -hydroxypregnenolone ( $\Delta^5$ -3-ketosteroid) by  $\Delta^5$ - $3\beta$ -hydroxysteroid dehydrogenase occurs prior to 20 reduction or vice versa. A kinetic study might provide information concerning which pathway is predominant.

The fact that the  $17\alpha,20\alpha(20\beta)$ -dihydroxypregnenolone could not be isolated in these experiments does not mean that the compounds are not possible metabolites of  $17\alpha$ -hydroxypregnenolone.

It has been suggested by Axelrod et al. (5) and Lynn and Brown (66) that the pregn-4-ene- $17\alpha,20\alpha$ -diol-3-one isolated by them from ovarian and testicular incubations could be an intermediate precursor of androstenedione. Evidence against this concept was provided by the investigations of Fevold and Eik-Nes (36), Ellis (29) and Dominguez (26). Fevold and Eik-Nes (36) demonstrated that the  $20\alpha$ -isomer was not metabolized significantly to other products by English sparrow testicular tissue, and indicated that the reduction of the 20-ketone of

17 $\alpha$ -hydroxyprogesterone appeared to be a physiological irreversible reaction.

Ellis and Berliner (29) reported that 17 $\alpha$ ,20 $\alpha$ -dihydroxyprogesterone was biotransformed into testosterone very slowly in mouse testes. This statement was reinforced by the work of Dominguez (26). He tested the role of 17 $\alpha$ ,20 $\alpha$ -dihydroxyprogesterone in the biosynthesis of androstenedione and testosterone in normal testes and observed that 17 $\alpha$ -hydroxyprogesterone was readily converted to androstenedione and testosterone while pregn-4-ene-17 $\alpha$ ,20 $\alpha$ -diol-3-one did not seem to be directly transformed to androstenedione and testosterone in appreciable or measurable amounts without previous conversion to 17 $\alpha$ -hydroxyprogesterone. However, the conversion of 20 $\alpha$ -glycol to 17 $\alpha$ -hydroxyprogesterone was limited at all times unless 17 $\alpha$ -hydroxyprogesterone had been almost completely metabolized. It appears that reduction of the 20-keto group of 17 $\alpha$ -hydroxyprogesterone by 20 $\alpha$ -hydroxy-dehydrogenase is not a readily reversible reaction.

Fevold and Eik-Nes (36) also reported that 20 $\alpha$ -isomer was androgenically inactive in the sparrow beak assay and inhibited side chain splitting enzyme (C-17,20,21-desmolase). However, the significant function of these two steroids in the living organism needs further investigation.

In the course of studies on the biosynthetic pathways of estrogens, the functions of pregnenolone, progesterone and androgens acting as precursors of estrogens synthesis in the ovarian tissue have been extensively investigated (96,6,112,50,86,107,5,40).

Estrogens can arise from pregnenolone via androgens by two different pathways. The classical  $\Delta^4$ -pathway which involves the formation of testosterone via progesterone, 17 $\alpha$ -hydroxyprogesterone and androstenedione. It was first elucidated by Slaunwhite and Samuels (93) in the testicular tissue and later Solmon et al. (96) reported a  $\Delta^4$ -pathway exists from progesterone to estrogens in bovine ovarian tissue. This pathway has been verified by several other workers (86,28,29). An alternative  $\Delta^5$ -pathway has been first suggested in testicular tissue by Neher and Wettstein (78). This  $\Delta^5$ -route of synthesis of testosterone involves 17 $\alpha$ -hydroxypregnenolone, dehydroepiandrosterone and androstenedione as intermediates. Ryan and Smith (87) demonstrated that  $\Delta^5$ -route is a more active pathway of estrogen biosynthesis in the human ovary. This alternative pathway in gonadal tissue has been confirmed by several other workers (57,38,39,109,37).

Fevold and Pfeiffer (37) investigated androgen biosynthesis in phalarope ovary incubated with prenenolone and found that  $\Delta^5$ -route is the predominant pathway and androstenedione is an intermediate in testosterone biosynthesis. This finding is contrary to some of the evidence in the mammalian gonadal tissue concerning the metabolic pathways of testosterone formation which involves androstenediol as an intermediate, thus by passing androstenedione (9,38,82,29,94).

The conversion of C-19 steroids to estrogens has been amply demonstrated (75,6,109). The fact that C-19-hydroxyl compound is an intermediate in estrogen biosynthesis is strongly indicated in ovaries and placenta (73,84,74,110). Wilcox and Engel (110) demonstrated that 19-hydroxyandrostenedione is an obligatory intermediate and 19-hydroxy-

lation is the rate limiting step in the formation of estrogens in placenta. However, whether 19-hydroxyandrostenedione or 19-hydroxytestosterone would be the obligatory intermediate of estrogen biosynthesis in phalarope ovary needs further investigation.

Since the ratio of radioactive androstenedione to radioactive testosterone in phalarope ovaries incubated with pregnenolone-7- $\alpha$ - $^3$ H was markedly less than one in the small ovaries and one or greater in the larger ovaries, it was suggested that the relative increase in the androstenedione formation during the period of ovarian development might favor estrogen biosynthesis, if 19-hydroxyandrostenedione is an obligatory intermediate and 19-hydroxylation is the rate limiting step as in the case of placenta (37). However, since this ratio depends mainly on the 17 $\beta$ -hydroxysteroid dehydrogenase present in the gland, the biosynthesis of estrogens from androgens in the phalarope ovary can not be solved unless further knowledge concerning the aromatization steps, level of aromatizing enzyme, rate limiting step, obligatory intermediate and activity of 17 $\beta$ -hydroxysteroid dehydrogenase is available.

The classical idea of estriol biosynthesis was thought to be transformation from estrone and 17 $\beta$ -estradiol. It has been well demonstrated in the human ovary (112,95), in human fetal liver (32) and rat liver (42). It was also isolated from human urine after administration of 17 $\beta$ -estradiol (11,22). Recently, Ryan (85) demonstrated that estriol can be produced from aromatization of androst-5-ene-3 $\beta$ ,16 $\alpha$ ,17 $\beta$ -triol and via 16 $\alpha$ -hydroxyestrone as an intermediate in human placenta. Furthermore, 16 $\alpha$ -hydroxyprogesterone has also been reported to be a precursor

of estriol biosynthesis by sow ovary (56). Which pathway is the predominant route in the phalarope ovary is not known. It might depend on the substrate specificity of the 16-hydroxylase, activity of the 16-hydroxylase present in the gland and the rate limiting step and aromatization rate of 16-hydroxyl C-19 steroids compared to C-19 steroids.

Since the attempt to isolate 16 $\alpha$ ,17 $\alpha$ -dihydroxyprogesterone from 17 $\alpha$ -hydroxyprogesterone failed in the sow ovary (56), this might indicate that the 17 $\alpha$ -hydroxyl group could interfere with the 16 $\alpha$ -hydroxylase enzyme system. It is thought that if estriol could be formed from 17 $\alpha$ -hydroxypregnenolone or 17 $\alpha$ -hydroxyprogesterone in the present experiments, possibly the classical pathway would be preferred. However, this problem needs further investigation.

Another partially identified phenolic compound is 16-oxo-17 $\beta$ -estradiol. Since 16 $\alpha$ -hydroxyestrone readily undergoes transformation to 16-oxo-17 $\beta$ -estradiol in alkali solution during the extraction of the phenolic fraction by aqueous alkali from ether (72), it is suspected that the partially identified 16-oxo-17 $\beta$ -estradiol might be an artifact produced from 16 $\alpha$ -hydroxyestrone.

The attempt to isolate estrogens from phalarope ovarian tissue incubated with 17 $\alpha$ -hydroxypregnenolone and 17 $\alpha$ -hydroxyprogesterone was unsuccessful in the present experiment. Only partial characterization was achieved. Possible reasons for this lack of success could be the low recovery of estrogens from the incubation medium, insufficient amount of estrogens synthesized, and also the possible deleterious effect of the prolonged storage of the tissue in the frozen state on its ability to synthesize estrogens.



VI. SUMMARY

$17\alpha$ -Hydroxypregnenolone- $7\text{-}^3\text{H}$  and  $17\alpha$ -hydroxyprogesterone- $4\text{-}^{14}\text{C}$  have been incubated with homogenized Wilson's phalarope ovarian tissue in Krebs-Ringer phosphate buffer (pH 7.35) containing ATF, DPN, TPN, sodium fumarate, nicotinamide, glucose, glucose-6-phosphate and glucose-6-phosphate dehydrogenase as cofactors and additives. The incubations were performed in a shaking incubator at  $41^\circ\text{C}$  for three hours. Following extraction and paper chromatography, two polar non-phenolic compounds were identified by comparing the chromatographic mobilities of the parent steroids, the acetate derivatives and the oxidation products with authentic standards. It was shown that  $X_1$  is pregn-4-ene- $17\alpha,20\alpha$ -diol-3-one and  $X_2$  is pregn-4-ene- $17\alpha,20\beta$ -diol-3-one. Some phenolic steroids were partially characterized as estrone, estriol and  $16\text{-oxo-}17\beta$ -estradiol. However, due to the limited amount of these metabolites, no further investigation could be carried out.

VII. BIBLIOGRAPHY

1. Acevedo, H. F., Axelrod, L. R., Ishikawa, E., and Takaki, F. 1961. Steroidgenesis in human foetal testes. Program 43rd Meeting Endocrine Soc. p. 22.
2. Allen, E., and Doisy, E. A. 1923. An ovarian hormone: primary report on its localization, extraction and partial purification and action in test animal. J. Am. Med. Assoc. 81, 819.
3. Allen, W. M. 1950. A simple method for analyzing complicated absorption curves of using in the colorometric determinations urinary steroids. J. Clin. Endocrinol. 10, 71.
4. Attal, J., Hendeles, S. M., and Eik-Nes, K. B. 1967. Determination of free estrone in blood plasm by gasphase chromatography with electron capture detection. Anal. Bioshem. 20, 394.
5. Axelrod, L. R., and Goldzieher, J. W. 1962. Polycystic ovary III. Steroid biosynthesis in normal and polycystic ovarian tissue. J. Clin. Endocrinol. 22, 431.
6. Baggett, B., Engel, L. L., Savard, K., and Dorfman, R. I. 1956. The conversion of testosterone-3-<sup>14</sup>C to <sup>14</sup>C-17 $\beta$ -estradiol by human ovarian tissue. J. Biol. Chem. 221, 931.
7. Baggett, B., Engel, L. L., Balderas, L. and Lanman, G. 1959. Conversion of <sup>14</sup>C-testosterone to <sup>14</sup>C-estrogenic steroids by endocrine tissues. Endocrinology 64, 600.
8. Barton, G. M., Evans, R. S. and Gardner, J. A. S. 1952. Paper chromatography of phenolic substance. Nature 70, 249.
9. Baulieu, E. E., Wallace, E. and Lieberman, S. 1963a. The conversion in vitro of  $\Delta^5$ -androstene-3 $\beta$ ,17 $\beta$ -diol-17 $\alpha$ -<sup>3</sup>H to testosterone-17 $\alpha$ -<sup>3</sup>H by human adrenal and placental tissue. J. Biol. Chem. 238, 1316.
10. Baulieu, E. E. and Robel, P. 1963b. Androst-5-ene-3 $\beta$ ,17 $\beta$ -diol-17 $\alpha$ -<sup>3</sup>H to testosterone-17 $\alpha$ -<sup>3</sup>H and 5 $\alpha$  and 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol-17 $\alpha$ -<sup>3</sup>H in vivo. steroids 2, 111.
11. Beer, C. T. and Gallapher, T. F. 1955. Extraction of estrogen metabolites by human: 1. fate of small doses of estrone and 17 $\beta$ -estradiol. 2. fate of large doses of 17 $\beta$ -estradiol after intramuscular and oral administration. J. Biol. Chem. 214, 335.
12. Bent, A. C. 1960, "Life histories of North American birds," 1, 259., Harper, New York.

13. Breuer, H., Nocke, L. and Knuppen, R. 1958. Reduction of 16 $\alpha$ -hydroxyestrone and 16-oxo-17 $\beta$ -estradiol. *J. Physiol. Chem.* 311, 275.
14. Breuer, H., Knuppen, R. and Pangels, G. 1959. Metabolism of 16-keto-estrone in human tissues. *Acta. Endocrinol.* 30, 247.
15. Breuer, H., Knuppen, R., Orttepp, R., Pangels, G. and Puck, A. 1960. Biogenesis of 6-hydroxylated estrogens in human tissues. *Biochim. Biophys. Acta.* 40, 560.
16. Breuer, H. 1962. The metabolism of the natural strogens. *Vitamins and Hormones* 20, 285-335. Academic Press. N. Y.
17. Brown, J. B. 1955. Method for urinary estrogens determination. *Biochem. J.* 60, 185.
18. Brown, J. B. and Marrian, G. F. 1957. The metabolic reduction of 16-hydroxyestrone to estriol in man. *J. Endocrinol.* 15, 307.
19. Butenandt, A. 1929. Progynon, a crystalline female sexual hormone. *Naturwissen-schaften* 7, 879.
20. Butenandt, A. and Ziegner, E. V. 1930. The female sexual hormone IV. The physiological activity of the crystallized female sexual hormone in the Allen-Doisy test. *Zoo. Physiolo.* 88, 1.
21. Butt, W. R. 1967. *Hormone Chemistry*. p. 278-299, D. Van Nortrand Company LTD, London.
22. Diczfalusy, E., Menini, E., Tillinger, K. G. 1959. Studies on estrogen metabolism in new born boys. *Acta Endocrinol.* 30, 539.
23. Doisy, E. A., Veler, C. D. and Thayers, S. A. 1930. The preparation of the crystalline ovarian hormone from the urine of pregnant women. *J. Biol. Chem.* 86, 449.
24. Doisy, E. A., Mac Corquodale, D. W. and Thayer, S. A. 1936. Isolation of the principal estrogenic substance of liquor folliculi. *J. Biol. Chem.* 115, 435.
25. Dominguez, O. V. 1961. Biosynthesis of steroids by testicular tumors complicating congenital adrenocortical hyperplasia. *J. Clin. Endocrinol. Metab.* 21, 663.
26. Dominguez, O. V. 1966. Biosynthesis of androgens from C<sub>21</sub>-steroids exhibiting differences in their side chain. *Steroids* 7, 455.
27. Dorfman, R. R. and Ungar, F. 1965. Metabolism of steroid hormones. p. 132-135, Academic Press, New York.

28. Eik-Nes, K. B. and Hall, P. F. 1962. Secretion of testosterone in anesthetized dogs. Proc. Soc. Exp. Biol. Med. 111, 280.
29. Ellis, L. C. and Berliner, P. L. 1965. Sequential biotransformation of 5-pregnenolone-7- $\text{L}^3\text{H}$  and progesterone-4- $\text{C}^{14}$  into androgens by mouse testes. Endocrinology 76, 59.
30. Engel, L. L., Slaunwhite, W. R. Jr., Carter, P. and Nathanson, I. T. 1950. Extraction procedure for urinary or plasma estrogens. J. Biol. Chem. 185, 255.
31. Engel, L. L., Baggett, B. and Carter, P. 1957. Metabolism of  $17\beta$ -estradiol-16- $\text{C}^{14}$ : isolation of 2-methoxy-estrone- $\text{C}^{14}$ . Endocrinology 61, 113.
32. Engel, L. L. and Baggett, B. and Halla, O. M. 1958. The formation of  $^{14}\text{C}$ -labelled estriol from 16- $^{14}\text{C}$ -estradiol-17 $\beta$  by human fetal liver slices. Biochim. Biophys. Acta 30, 435.
33. Fevold, H. R. 1961. In vitro progesterone metabolism by avian testicular tissue. Ph. D. Thesis.
34. Fevold, H. R. and Eik-Nes, K. B. 1961. In vitro progesterone metabolism by avian testicular tissue homogenates. Federation Proc. 20, 197.
35. Fevold, H. R. and Eik-Nes, K. B. 1962. Progesterone metabolism by testicular tissue of the English sparrow (Passer domesticus) Gen. and Comp. Endocrinol. 2, 506.
36. Fevold, H. R. and Eik-Nes, K. B. 1963. Progesterone metabolism by testicular tissue of the English sparrow (Passer domesticus) Gen. and Comp. Endocrinol. 3:335.
37. Fevold, H. R. and Pfeiffer, E. W. 1968. Androgen production in vitro by phalarope gonadal tissue homogenates. Gen. and Comp. Endocrinol. 10, 26.
38. Gospondarowicz, D. 1964a. The action of follicle stimulating hormone and of human chorionic gonadotrophin upon steroid synthesis by rabbit ovarian tissue in vitro. Acta Endocrinol. 47, 293.
39. Gospodarowica, D. 1964b. The in vitro production of androgens by follicular tissue of rabbits. Acta Endocrinol. 47, 306.
40. Griffiths, K., Grant, J. K. and Symington, T. J. 1964. Steroid biosynthesis in vitro by granulosa-theca cell tumor tissue. J. Endocrinol. 30, 247.

41. Hagen, A. A. and Eik-Nes, K. B. 1964. Testosterone biosynthesis in the canine in vitro following infusion of  $17\alpha$ -hydroxyprogesterone- $4\text{-C}^{14}$  and dehydroepiandrosterone- $7\text{-}\alpha\text{-}^3\text{H}$  via the spermatic artery. *Biochim. Biophys. Acta* 90, 593.
42. Hagopian, M. and Levy, L. 1958. The conversion of  $16\text{-}^{14}\text{C}$ - $17\beta$ -estradiol to estriol by isolated rat livers. *Biochim. Biophys. Acta* 30, 641.
43. Haines, W. J. and Drake, N. A. 1950. Fluorescence scanner for evaluation of papergrams of cortical hormones. *Federation Proc.* 9, 180.
44. Hall, P. F., Sozer, C. C. and Eik-Nes, K. B. 1964. Formation of dehydroepiandrosterone during in vivo and in vitro biosynthesis of testosterone by testicular tissue. *Endocrinology* 74, 35.
45. Hayano, M., Longchamp, J., Kelley, W., Gual, C. and Dorfman, R. I. 1960. Studies relative al biosynthese de estrogenos per microsomas placental human. *Acta Endocrinol. suppl.* 51, 351.
46. Heard, R. D. H., Jacobs, R., O'Donnell, V., Person, F. G., Suffrau, J. C., Solmon, S. S., Thompson, L. M., Willoughby, H. and Yates, C. H. 1954. *Recent Progress in Hormone Research* 9, 383.
47. Heard, R. D. H., Bligh, E. G., Cann, M. C., Jillinck, P. H., O'Donnell, V., Rao, B. C. and Welb, J. L. 1956. *Recent Progress in Hormone Research.* 12, 45.
48. Hechter, O., Zaffaroni, A., Jacobsen, R. P., Levy, H., Jeanloz, R. W., Schenker, W. and Pincus, G. 1951. *Recent Progress in Hormone Research.* 6, 205.
49. H6hn, E. O. and Cheng, S. C. 1965. Gonadal steroid hormones in phalaropes in comparison with those of other birds. *Amer. Zoo.* 5, 658 (Abstract).
50. Hollander, N., and Hollander, V. P., and Tull, L. 1958. Effect of follicle stimulating hormone on the biosynthesis in vitro of estradiol- $17\beta$  from acetate- $\text{C}^{14}$  and testosterone- $4\text{-C}^{14}$ . *J. Biol. Chem.* 233, 1097.
51. Huang, W. Y. and Pearlman, W. H. 1962. The corpus luteum and steroid hormone formation. *J. Biol. Chem.* 237, 1060.
52. Idler, D. R., Fagerlund, U. H. M. and Ronald, A. B. 1960. Isolation of pregn- $4\text{-ene-}17\alpha,20\beta\text{-diol-}3\text{-one}$  from the plasma of Pacific Salmon (*Oncorhynchus nerka*). *Biochem. Biophys. Res. Commun.* 2, 133.
53. Johns, J. E. and Pfeiffer, E. W. 1963. Testosterone-induced incubation patches of phalarope birds. *Science* 140, 1225.

54. Johns, J. E. 1964. Testosterone-induced nuptial feathers in phalaropes. *Condor* 66, 449.
55. Kadis, B. 1964a. Estrogen biosynthesis by sow ovary. *Biochemistry* 3, 2016.
56. Kadis, B. 1964b. Conversion of 16 $\alpha$ -hydroxyprogesterone to estriol by sow ovary. *Biochim. Biophys. Acta* 82, 649.
57. Kahnt, F. W., Neher, R., Schmid, K., and Wettstein, A. 1961. Bildung von 17 $\alpha$ -hydroxy- $\Delta^5$ -pregnenolon und 3 $\alpha$ -hydroxy-17-keto- $\Delta^5$ -androstendiol(DHA) in Nebennieren und Testesgewebe. *Experientia* 17, 19.
58. King, R. J. B. 1960. The demonstration of 16-hydroxy-steroid dehydrogenase in rat kidney. *Biochem. J.* 76, 7 P.
59. Klebe, J. F., Finkheiner, H., White, D. M., Ritter, A., Birkober, L. and Giessler, W. 1966. Silylations with Bis-(trimethyl silyl) acetamide a highly reactive silyl donor. *J. Am. Chem. Soc.* 88, 3390.
60. Langer, L. J. and Engel, L. L. 1958. Human placental 17 $\beta$ -estradiol dehydrogenase. *J. Biol. Chem.* 233, 583.
61. Levitz, M., Spitzer, J. R. and Twombly, G. H. 1956. The synthesis of 16-keto-estradiol-17 $\beta$ -16-C<sup>14</sup>. *J. Biol. Chem.* 222, 981.
62. Levy, H., Jeariloz, R. W., Jacobson, R. P., Hechter, O., Schenker, V. and Pincus, G. 1954. Chemical transformations of steroids by adrenal tissue perfusion. *J. Biol. Chem.* 211, 867.
63. Levy, H., Saito, T., Takeyana, S., Merrill, A. P. and Schepis, J. P. 1963. The conversion of 17 $\alpha$ -hydroxyprogesterone into prege-4-ene-3 $\alpha$ ,17 $\alpha$ -diol-20-one and other substances by perfusions through bovine adrenals. *Biochim. Biophys. Acta* 69, 1968.
64. Libos, B. P. and Diczfalsy, E. 1962. Separation and characterization of steroid estrogens by means of thin-layer chromatography. *Acta. Endocrinol.* 40, 60.
65. Longchamp, J. E., Gual, C., Eienstein, M. and Dorfman, R. I. 1960. 19-Hydroxy- $\Delta^4$ -androstene-3,17-dione and intermediate in estrogen biosynthesis. *Endocrinology* 66, 416.
66. Lynn, W. S. Jr., and Brown, K. H. 1958. The conversion of progesterone to androgens by testes. *J. Biol. Chem.* 232, 1015.
67. Marrian, G. F. 1929. The chemistry of estrin. (I): preparation from urine and separation from an unidentified solid alcohol. *Biochem. J.* 23, 1090.

68. Marrian, G. F. 1939. Some aspects of the intermediary metabolism of the steroid hormones. Bull. N. Y. Acad. Med. 15, 27.
69. Marrian, G. F. and Bauld, W. S. 1954. Hydrolysis of the conjugated estrogens in human urine. Biochem. J. 58, 367.
70. Marrian, G. F. and Bauld, W. S. 1955. Isolation of 16 $\beta$ -epiestriol from the urine of pregnant women. Biochem. J. 59, 136.
71. Marrian, G. F. and Watson, E. J. D. and Panattoni, M. 1957a. The isolation of a ketonic dehydroxy Kober chromagen from the urine of pregnant women. Biochem. J. 65, 12.
72. Marrian, G. F., Loke, K. H., Watson, E. J. D. and Panattoni, M. 1957b. 16 $\alpha$ -Hydroxyestrone in the urine of pregnant women. Biochem. J. 66, 60.
73. Meyer, A. S. 1955. Conversion of 19-hydroxy- $\Delta^4$ -androstene-3,17-dione to estrone by endocrine tissue. Biochim. Biophys. Acta 17, 441.
74. Morato, T., Hayano, M., Dorfman, R. I. and Axelrod, L. R. 1961. The intermediate steps in the biosynthesis of estrogens from androgens. Biochem. Biophys. Res. Comm. 6, 334.
75. Nathanson, I. T., Engel, L. L., Kelley, R. M., Ekman, G., Spaulding, K. H. and Elliott, J. 1952. Effect of androgens on urinary excretion of ketosteroids and estrogens. J. Clin. Endocrinol. and Meta. 12, 1172.
76. Neher, M. and Wettstein, A. 1960a. Steroids und andere inhaltsstoffe aus stierhoden. Helv. Chim. Acta. 43, 1628.
77. Neher, M., and Wettstein, A. 1960b. Isolatierung und identifizierung neuer nebennierensteroid; charakterisierung weiterer inhaltsstoffe. Helv. Chim. Acta 43, 1171.
78. Neher, R. and Wettstein, A. 1960. Occurrence of  $\Delta^5$ - $3\beta$ -hydroxy-steroids in adrenal and testicular tissue. Acta Endocrinol. 35, 1.
79. Neher, R. 1964. Steroid Chromatography. p. 239-249. Elsevier publishing company. New York.
80. Nicoll, C. S., Pfeiffer, E. W. and Fevold, H. R. 1967. Prolactin and nesting behavior in phalaropes. Gen. and Comp. Endocrinol. 8, 611.
81. Rao, B. and Heard, R. D. H. 1957. Biogenesis of the corticosteroids. (II); conversion of progesterone-4- $C^{14}$  in cell free dog adrenal preparation. Arch. Biochem. Biophys. 66, 504.

82. Rosner, J. M., Horita, S. and Forsham, P. H. 1964. Androstenediol, a probable intermediate in the in vitro conversion of dehydroepiandrosterone to testosterone by the rabbit testes. *Endocrinology* 75, 229.
83. Ryan, K. J. 1958. Conversion of androstenedione to estrone by placental microsomes. *Biochim. Biophys. Acta* 27, 658.
84. Ryan, K. J. 1959a. Biological aromatization of steroids. *J. Biol. Chem.* 234, 268.
85. Ryan, K. J. 1959b. Metabolism of C-16-oxogenated steroids by human placenta: the formation of estriol. *J. Biol. Chem.* 234, 2006.
86. Ryan, K. J. and Smith, O. W. 1961a. Biogenesis of estrogens by the human ovary II: conversion of progesterone-4-C<sup>14</sup> to estrone and estradiol. *J. Biol. Chem.* 236, 710.
87. Ryan, K. J. and Smith, O. W. 1961b. Biogenesis of estrogens by human ovary III: formation of neutral steroid intermediate. *J. Biol. Chem.* 236, 2207.
88. Ryan, K. J. and Magendantz, H. 1964. Isolation of a new precursor 3 $\beta$ ,16 $\alpha$ -dihydroxy-androst-5-ene-17-one. *Federation Proc.* 23, 275.
89. Samuel, L. T., Helmreich, M. L., Laster, M. B. and Reich, H. 1961. An enzyme in endocrine tissues which oxidizes  $\Delta^5$ -3-hydroxy-steroids to  $\alpha,\beta$ -unsaturated ketone. *Science* 113, 490.
90. Sandor, T. and Lantheir, A. 1960. Biosynthesis of two steroid glycols from 17 $\alpha$ -hydroxyprogesterone by surviving human ovarian slices. *Can. J. Biochem. Physiol.* 38, 1167.
91. Savard, K., Dorfman, R. I., Baggett, B. and Engel, L. L. 1956. Biosynthesis of androgens from progesterone by human testicular tissue in vitro. *J. Clin. Endocrinol. and Metab.* 16, 1629.
92. Shikita, M., Kikizoki, A., and Tamaoki, B. 1964. Pathway of formation of testosterone from 3 $\beta$ -hydroxy-pregn-5-ene-20-one by rat testicular microsomes. *Steroids* 4, 521.
93. Slaunwhite, W. R. Jr. and Samuel, L. T. 1956. Progesterone as a precursor of testicular androgens. *J. Biol. Chem.* 220, 341.
94. Slaunwhite, W. R. Jr. and Baggett, M. J. 1965. In vitro testosterone synthesis by rat testicular tissue. *Steroids* 6, 722.
95. Smith, O. W. 1960. Estrogen in the ovarian fluids of normally menstruating women. *Endocrinology* 67, 689.



96. Solomon, S., Wiele, R. V. and Lieberman, S. 1956. The in vitro synthesis of 17 $\alpha$ -hydroxyprogesterone and androst-4-ene-dione-3,17-dione from progesterone by bovine ovarian tissue. J. Am. Chem. Soc. 78, 5453.
97. Stahle, E. 1965. Thin-layer chromatography. p. 11-34. Academic Press. N. Y.
98. Starka, A. L., Sanda, V. and Stastny, J. 1966. The role of 19-hydroxyepiandrosterone in estrogen biosynthesis. Eur. J. Steroids 1, 309.
99. Stimmel, B. F., Grollman, A., Huffman, M. N., Lott, M. M. and Ashman, J. 1948. The conversion of 16-ketoestrone to estradiol in vivo. J. Biol. Chem. 176, 461.
100. Stimmel, B. F., Grollman, A. and Huffman, M. M. 1950. Metabolism of 16-ketoestrone and 16-keto-17 $\alpha$ -estradiol in man. J. Biol. Chem. 184, 677.
101. Stimmel, B. F. 1958. Metabolism of 16-ketoestrone in man. Federation Proc. 17, 1253.
102. Sweat, M. L. 1954. Silica gel microcolumn for chromatographic resolution of cortical steroids. Anal. Chem. 26, 1964.
103. Troen, P. 1961. Perfusion studies of the human placenta II: metabolism of 17 $\beta$ -estradiol-C<sup>14</sup> with or without human chorionic gonadotrophin. J. Clin. Endocrinol. Metab. 21, 895.
104. Turfitt, G. E. 1946. Microbiological degradation of steroids III: oxidation of cholesterol by Proactinomyces species. Biochem J. 40, 79.
105. Umbreit, W. W., Barris, R. H. and Stauffer, J. F. 1957. Manometric techniques. p. 49, 3rd edition, Burgess Publ. Co., Minneapolis.
106. University of Montana Computer Center. (Nuclear Chicago Liquid-Scintillation Manual).
107. Warren, J. C. and Salhanick, H. A. 1961. Steroid biosynthesis in the human body. J. Clin. Endocrinol. Metab. 21, 18.
108. Weliky, J. and Engel, L. L. 1961. 17 $\alpha$ -Hydroxypregnenolone as a precursor for cortisol. Federation Proc. 20, 179.
109. West, C. D. and Naville. 1962. The in vitro conversion of dehydroepiandrosterone-4-C<sup>14</sup> to estrogens by ovarian tissue. Biochem. 1, 645.

110. Wilcox, R. B. and Engel, L. L. 1965. Kinetic studies on the role of 19-hydroxyandrost-4-ene-3,17-dione in estrogen biosynthesis. *Steroids* 6 suppl. I. 49.
111. Wilcox, R. B. and Engel, L. L. 1965. The aromatization of 10-methyl and 10-hydroxy methyl steroids by human placental microsomes. *Steroids* 6 suppl. II. 249.
112. Wotiz, H. H., Davis, J. W., Lemon, H. M. and Gut, M. 1956. Studies in steroid metabolism. V. : the conversion of testosterone-4-C<sup>14</sup> to estrogens by human ovarian tissue. *J. Biol. Chem.* 222, 487.
113. Zaffaroni, A. and Burton, R. B. 1951. Identification of corticosteroids of beef adrenal extract by paper chromatography.
114. Zaffaroni, A. 1953. Micromethods for the analysis of adrenocortical steroids. *Recent Progress of Hormone Research* 8, 51.
115. Zander, J. 1958. Steroids in the human ovarian. *J. Biol. Chem.* 232, 117.

## PART B

### IN VITRO STUDIES OF $17\beta$ -HYDROXYSTEROID DEHYDROGENASE ACTIVITY IN AVIAN OVARIAN AND TESTICULAR TISSUES

#### I. INTRODUCTION

$17\beta$ -Hydroxysteroid dehydrogenase ( $17\beta$ -HSD) is a key enzyme required for testosterone biosynthesis in phalarope ovarian and testicular tissue. The enzyme possesses high affinity and structural specificity for its substrate. It is thought that a correlation between testosterone biosynthetic capacity and enzyme level may exist in these tissues. The purpose of these experiments is to measure in vitro activity of  $17\beta$ -hydroxysteroid dehydrogenase in phalarope gonadal tissues.

During the earlier phase of the breeding cycle, the female phalaropes apparently secrete more androgen than the males (26), and testosterone but not estradiol induces nuptial feathers in phalaropes (29). It appears that the high ovarian content of testosterone is related to the brighter plumage and more aggressive behavior of females than males in this species. Furthermore, Fevold and Pfeiffer (23) reported that there was a marked shift favoring androstenedione production over testosterone production in the larger phalarope ovaries incubated with  $17\alpha$ -hydroxyprogesterone and  $17\alpha$ -hydroxypregnenolone as substrates. It was suggested that testosterone production would decrease as the follicles approached maturity. On the other hand, since the male phalaropes could not produce sufficient androgen in early spring to stimulate development of the bright female type breeding plumage and

since testosterone and prolactin are necessary for the development of the brood patch found only in the male of the species (28), it would be anticipated that the male would increase the production of testosterone in the late spring of the breeding cycle. Therefore, the secretion of testosterone by the phalarope gonads might follow the curve presented in Figure 1 (Part A, page 3), as mentioned in the previous hypothesis. The present experiments were made to investigate this hypothesis by measuring the activity of  $17\beta$ -hydroxysteroid dehydrogenase in the phalarope gonadal tissues.

In vitro  $17\beta$ -hydroxysteroid dehydrogenase activity in ovarian and testicular homogenates from phalaropes was measured by the conversion rate of androstenedione to testosterone as described by Schoen (48).

## II. HISTORICAL REVIEW

### A. Avian gonadal cycles

The seasonal character of reproductive periodicity in the wild birds has been extensively investigated since the work of Schäfer (47). Although such cycles occur in both male and female birds, the testicular cycle has been studied more thoroughly while the ovarian cycle has received little attention.

In general, during the sexually inactive period, the sex glands of most wild birds regress to tiny rudiments. In the testis at this time, one finds only inactive spermatogonia, in the ovary only small ovocytes. At the approach of the breeding season, these glands enlarge very rapidly. Spermatogenesis proceeds quickly to the production of millions of ripe spermatozoa. Epididymis and vas deferens enlarge correspondingly and become filled with seminal fluid. In a similar way, the female genital organs develop. The thin and straight oviduct becomes convoluted and very corpus, due to the enormous development of its glanular epithelium.

Very few reports published discuss the annual gonadal cycles of Wilson's phalarope. However, the gonadal cycles of phalarope is similar to that of other temperature zone birds. Bent (?) reported that young birds of the Wilson's phalarope are in winter plumage by September. A partial prenuptial molt in April and May, involving the tail, the wing coverts and all the body feathers, produces the brilliant plumage of the female and duller plumage of the male. The growth of this plumage is correlated with the onset of aggressive courtship behavior at the start

of the breeding season. The date of egg laying varies from May 15 to June 24 in North America. In summer, the complete post nuptial molt produces the gray winter plumage in both sexes. Therefore, it is suggested that the gonadal cycles of phalarope might be correlated with that of the English sparrow (58,55).

In general, gonadal size is minimal during winter; begins to increase in late winter and early spring; reaches its maximum in late spring and early summer; decreases in summer and early fall; and remains at this stage until the start of another cycle (22). Witschi (58) found that the testis of the English sparrow increases in weight 500 fold or more and the ovary in the English sparrow increases from less than 10 mg to 500 and more milligrams from winter to spring or summer. A typical annual cycle is illustrated in Figure 1. It is believed that some environmental and physiological factors control the seasonal sexual cycle of birds. These factors include the length of daily photoperiods, temperature, food supply, gonadotrophins, sex hormones secretion and perhaps others.

Scháfer (48) was one of the first to suggest that the constant change in the length of daily photoperiod might be considered as a factor in the avian sexual cycle. Rowan (44) found that precocious spermatogenesis could be stimulated in sexually inactive male Juncos by adding several hours of artificial illumination to natural winter day lengths and thereby determined that the incidence of daily light is actually a factor in seasonal sexual activity. Further investigations of the relationship of photoperiod to seasonal sexual activity of birds were reported by




Figure 1. Typical annual gonadal cycle of English Sparrow. Modified from Witschi(1935)

———— Ovarian cycle  
----- Testicular cycle

Rowan (45, 46) and Bissonnette (8,9,10,11).

Bissonnette (10) demonstrated that red light stimulates testicular development to a greater degree than white light and green light inhibits development of the testis. Ringeon (42), Burger (16) and Benoit (6) agree that the far infrared and near infrared are not stimulatory, while the most effective wave lengths lie in the yellow-red. The minimum daily photoperiod required for gonadal stimulation is about ten hours for several species of birds (3,15). Some workers observed that the gonadal growth of birds stimulated by light was due to the stimulation of pituitary gonadotrophin secretion (4,5,38). Gonadotrophins secreted by the pituitary are believed to stimulate the gonads to produce sex hormones and to cause gametogenesis. The release of sex hormones is closely correlated with the development of the reproductive organs, secondary sexual characters, some sexually dimorphic characters and behavioral patterns.

The demonstration of a refractory period (38,40,60) indicates that a mechanism is incorporated which prevents the birds from responding to light and thus permits a "rest" before the bird returns to breeding condition. The duration of the refractory period in conjunction with the annual light cycle seems to control the general form of the annual reproductive cycle of many birds tested. Benoit (5) presented strong evidence that the anterior pituitary in domestic drakes has a refractory phase that may be independent of the gonads. First they showed that bilateral castration did not induce pituitary hypertrophy during the period while the testes were inactive. Secondly,



there is no compensatory testicular hypertrophy after unilateral castration. Müller (38) demonstrated that the inactive testes of adult and immature golden-crowned sparrow could not be activated by injection of pregnant mare serum. This suggests that the failure of testicular response is not due to a refractoriness of the testis. Lofts and Marshall (36) also give the evidence that it is the anterior pituitary and not the testis that becomes seasonally refractory.

Riley and Witschi (41) found that male English sparrows responded equally well at all seasons to injected gonadotrophin. Females, however, showed a seasonal response to the same treatment. The ovarian response to gonadotrophin was found to be poor in immature birds, but quite good immediately before ovulation. Breneman (13) also observed that ovaries of chicks are less responsive to pituitary extracts than the testes.

Breneman (14) reported that little effect on gonads and pituitary of the pullet is produced when either estriol or testosterone is administered alone, but when estrogen and androgen are administered simultaneously maximal stimulation of the reproductive system and pituitary occurs.

Romanoff and Romanoff (43) observed that oviducts in Leghorn pullets of 4 months averaged 1.1g but after the first ovulation the oviduct weight increases to 77.2 grams. Breneman (14) demonstrated that the ovarian growth of pullets does not occur until the interval between 115 and 126 days of post-hatching and the weight increases almost twelve times from 495.7 to 5781.1 mg. Therefore, pullets must have considerable

amounts of both androgen and estrogen present coincidental with the beginning of maximal ovarian growth. He also reported that maximal pituitary growth of pullets, from 5.56 to 8.23 mg, occurs between 115 and 126 days of post-hatching, while potency increases from 7.3 to 14.4 c.u.\* Obviously, gonadotrophin content of the pituitary is not inhibited by the gonadal hormones.

External temperature has no prohibitive effect in most birds tested. Rowan's original work was done at sub-zero temperature. Bissonnette and Csech induced pheasants to lay eggs in snow banks. Kendeigh compared temperature of 72°F with 36°F, for their effect on the English sparrow and noticed no difference in response due to temperature. However, some other reports indicate that the reproductive activity is depressed by cold (17).

It would seem that the neurohumoral mechanism stimulating the anterior pituitary will operate fully in the seasonal wild birds only if a combination of environmental events to which the species has evolved its reproductive response take place. If the environment is too dark, too cold or too hot, if there is a lack of water, food, a mate or of any other appropriate stimuli, the neural mechanism that governs the anterior pituitary will not operate or will operate partially, with resulting failure of spermatogenesis, ovulation or reproduction.

---


\* c.u. = a net increase of 35% in the weight of the testes of assay chicks over those of the control chicks.

## B. 17 $\beta$ -Hydroxysteroid dehydrogenase

17 $\beta$ -Hydroxysteroid dehydrogenases are widely distributed in the living organisms. They are pyridine-nucleotide linked enzymes which catalyze reversible oxidation of hydroxyl groups on the steroid nucleus (53). Either NAD or NADP or both may act as coenzymes for a specific 17 $\beta$ -HSD from different tissues.

One of these enzymes was first prepared by Talalay and Marcus (52) from *Pseudomonas testosteroni*. A placental 17 $\beta$ -HSD has been studied by Langer et al. (35) and Jarabak (27). The placental enzyme can utilize both NAD and NADP as coenzymes, the latter giving about one half of the initial rate of the former (34). However, the enzyme in the rabbit ovaries was found to be NADP predominant (19). All of the 17 $\beta$ -hydroxysteroid dehydrogenases investigated possess essential sulfhydryl groups and are inactivated by cupric, mercuric and ferric ions and activated by zinc (34).

The placental enzymes have an absolute steric specificity for the 17 $\beta$ -hydroxyl group, but the phenolic hydroxyl group is not absolutely necessary for the reaction between enzyme and substrate (35). Hagerman et al. (25) have demonstrated that the NAD and NADP dehydrogenations of estradiol are catalyzed by different enzymes. The reaction catalyzed by these enzymes are represented as follows:



Langer and Engel (34) suggested that 17 $\beta$ -HSD is identical to the 17 $\beta$ -estradiol mediated transhydrogenase in placental tissue and 17 $\beta$ -estradiol functions as a coenzyme or cosubstrate in a transhydrogenation

reaction catalyzed by the  $17\beta$ -hydroxysteroid dehydrogenase. The coenzyme function of  $17\beta$ -estradiol was also supported by Jarabak et al. (27) and Crist and Warren (18).

The reaction of conversion of testosterone to androstenedione has been studied in various organisms. Namely, in liver (50); in Penicillium lilacinum and Pseudomonas testosteroni (52), (54); in the ovary of rat, guinea, pig, human (20) and rabbit (19,21); in the testes of rat, rabbit (20,21) and human (59, 48). The  $K_{eq}$  values of these enzymes vary in the range of  $1-40 \times 10^{-9}$  at  $25^{\circ}\text{C}$  (37). Therefore, the enzymes favor the formation of the steroid alcohol. Most of the  $17\beta$ -HSD studied not only catalyze dehydrogenation reaction of testosterone but also some other steroids with  $17\beta$ -hydroxyl group, especially  $17\beta$ -estradiol. However, some rate difference exists in the dehydrogenation reactions of these steroids in various tissue (52,35,27,21). Since the enzymes examined for their substrate specificity are only partially purified, it is questionable whether the enzyme catalyzing the oxidation of C-17-hydroxyl function of testosterone and  $17\beta$ -estradiol is the same enzyme acting on different substrates or discrete enzymes for each substrate in the tissue. This problem still needs further investigation.

### III. EXPERIMENTAL MATERIALS AND PROCEDURES

#### A. Experimental animals

Source of birds and tissues was the same as Part A, p. 17, except testes of Wilson's phalarope and ovaries of northern phalarope in the first group of experiment were used.

B. Chemicals

1. Androstenedione-4-<sup>14</sup>C (Lot number CFA 248, Batch 3) with specific activity 34.8 mc/mole was obtained from the Nuclear Chicago Corporation. It was purified by paper chromatography in the heptane: benzene(1:1)/formamide system prior to use.

2. Testosterone-1,2-<sup>3</sup>H (Lot number 984-1 -41, Nuclear Chicago) had a specific activity of 38.8 mc/mole and was used as an internal standard after being purified by paper chromatography in the heptane: benzene(1:1)/formamide system.

3. Instant thin-layer chromatographic media was obtained from Gelman Instrument Company (Lot No. 28313), size 20x20 cm.

4. Other items were the same as in Part A, p. 18-19.

C. Equipment - See Part A, p. 20, 21.

D. Procedures

1. Substrate preparation

10.7 Microcuries of purified androstenedione-4-<sup>14</sup>C and 4.696 micromoles of non-radioactive androstenedione were added to the same tube and the solution was evaporated to dryness. The residue was redissolved in 10 ml solution of absolute ethanol:propylene glycol(1:1) prior to use.

2. Tissue preparation

Ovaries and testes of different weights were divided into twelve groups (Table 1), thawed, and homogenized in twelve separate Ten-Brock tissue grinders. The Krebs-Ringer phosphate buffer in which the tissues were homogenized had a pH of 7.35 and contained 0.04M nicotinamide.

Tissue to buffer ratio was 1:40. All tissue preparation was carried out at 0°C.

### 3. Preparation of incubation flask

All glassware was sterilized prior to use. Flasks used for the incubations were the same as in Part A, p. 22. One-tenth microcurie and 0.05  $\mu$ mole androstenedione-4-<sup>14</sup>C in 0.1ml of ethanol:propylene glycol (1:1 v/v) were generally added to the flasks. In some cases half or double this amount of substrate was used (Tables 3 and 4). The ethanol was evaporated. An aliquot of the substrate was taken during the initial and final period of substrate addition to the flasks. These aliquots were assayed for <sup>14</sup>C content by liquid scintillation spectrometry and the values averaged to calculate the amount of <sup>14</sup>C-androstenedione added to the flasks (Table 2).

After the ethanol was evaporated, 5.0 microliters (10  $\mu$ g) of Sigma Type VU glucose-6-phosphate dehydrogenase was added to each flask, followed by the addition of one ml of buffer containing all other cofactors. The final cofactors concentrations were the same as indicated in Part A, p. 22. Finally, one ml of the whole homogenated in buffer containing nicotinamide was added to each of flask. The flasks were gassed for one minute with a 95%O<sub>2</sub>-5%CO<sub>2</sub> immediately after the addition of the homogenate and tightly stoppered. Zero time control incubations were terminated immediately after the one minute gassing period by adding 5.0 ml diethyl ether:ethyl acetate(4:1v/v) to the incubation flask and placing in the freezer at -20°C.

### 4. Incubation

Table 1

Phalarope tissue used for incubation

Homog. No.	Sex	Bird No.	Gonad Wts (mg)	Homog. Vol. (ml)	Amt. Tissue mg/flask	No. of Flasks
1	♀	66-35*	37.0	2.5	14.8	2
2	♀	66-37	61.6	6.5	20.6	6
		66-36	70.4			
3	♀	66-20	147.4	6.5	22.7	6
4	♀	66-27	166.6	13.4	25.0	12
		66-18	168.8			
5	♀	66-6	219.0	7.8	25.0	6
6	♀	66-7	224.0	9.0	25.0	6
7	♀	66-19	302.6	12.1	25.0	6
8	♀	66-8	500.8	10.0	50.0	6
9	♀	66-29	2323.8	23.2	100.0	6
10	♂	66-33	443.0	8.9	50.0	6
11	♂	66-15	325.0	13.0	25.0	12
12	♂	66-16	217.0	8.7	25.0	6

\* Northern phalarope

After gassing the incubation flasks were placed immediately in a constant temperature, shaking water bath and incubated at 41°C for ten or twenty minutes. The reactions were stopped by the addition of the same organic solvent as mentioned above.

#### 5. Extraction

Testosterone-1,2-<sup>3</sup>H (~0.08 μc) was added to each incubation flask before initial extraction. The amount added was checked with each group of extraction flasks (Table 2). This added steroid was used as a chromatographic standard as well as for the calculation of estimated percent recovery figures. The extraction method was the same as stated in Part A, p. 24.

#### 6. Product purification, isolation and identification

a. The first chromatographic separation of extracted media was performed in the same way as for the separation of natural steroids as indicated in Part A, p. 25. The typical tracing of steroid metabolites on the paper chromatogram is shown in Figure 2. The chromatogram was divided into three parts. The first fraction corresponded the area of authentic testosterone and the third fraction was the unmetabolized androstenedione. The second fraction was the area between authentic testosterone and androstenedione. The steroids on the chromatogram strips were cut and eluted with 15 ml absolute ethanol and the solvent evaporated to dryness.

#### b. Further identification of product

Like fraction of the number one area from the first chromatograms were pooled and rechromatographed on silica gel thin-layer



Table 2

Total radioactivity of substrate and internal extraction standard added to the incubation flasks before and after incubation, respectively

Compound	DPM
<b>Androstenedione-4-<sup>14</sup>C</b>	
initial	229309
final	240989
<b>Testosterone-1,2-<sup>3</sup>H</b>	
flasks 1-32	149959
flasks 33-48	172844
flasks 49-60	184421
flasks 61-72	199130
flasks 73-80	37203




Figure 2. Tracing of the first chromatographic separation of radioactive metabolites isolated from incubations of phalarope gonadal tissues cell-free homogenate with androstenedione-4-<sup>14</sup>C substrate.

plates in the cyclohexane:ethyl acetate (50:50 v/v) system. Further chromatographic identification of metabolite was performed by comparing the mobilities of the parent compound and the products of acetylation, saponification and oxidation with authentic standards as described in Part A, pp. 26-27.

#### 7. Quantification of metabolites

The residue of each fraction eluted from the initial chromatogram was redissolved in 1.0 ml absolute ethanol and 0.1 ml duplicate were placed in liquid scintillation counting vials. After evaporation of the ethanol, ten ml of counting fluid were added to each vial. Radioactivity in all samples was quantified by counting the aliquots in the liquid scintillation spectrometer. The calculation of the amount of tritium and  $^{14}\text{C}$  present in each sample was carried out on an IBM 1620 data processing system using standard equations\* (Nuclear Chicago Liquid Scintillation Manual).

The activity of  $17\beta$ -hydroxysteroid dehydrogenase was calculated by the percent conversion rate of androstenedione to testosterone. The original values of percent conversion were adjusted by the percent recovery of testosterone. The zero time control values were then subtracted from this figure to obtain the true values per unit time.

---

\* I wish to thank Professor John Peterson for writing the program for these equations.

#### IV. RESULTS

##### A. Effect of substrate concentration on the velocity of the $17\beta$ -hydroxysteroid dehydrogenase reaction in ovarian and testicular tissues.

When 25.0 mg of ovarian tissue were used with amounts of substrate varying from 25.0-50.0  $\mu$ M, there was no significant variation in the velocity of the  $17\beta$ -hydroxysteroid dehydrogenase reaction (Figure 3). Likewise, a similar curve was obtained with increasing substrate concentration from 25.5-50.0  $\mu$ M with 25.0 mg of testicular tissue (Figure 3). These results indicate that the enzyme is saturated with the substrate in the present experiments at the 25  $\mu$ M substrate concentration used.

##### B. Rate of formation of testosterone from androstenedione in phalarope ovarian and testicular tissues.

The original data of the conversion rate of testosterone from androstenedione in various phalarope ovarian and testicular tissues were listed in Tables 3 and 4. These data have been corrected for the percent recovery of testosterone. The average percent conversion of androstenedione to testosterone was obtained by using the method of least squares. The values after correcting to 100 mg tissue weight basis were plotted against incubation times and shown in Figures 4 and 5. The slope of the lines in Figure 4 varies with ovarian weight but is not directly proportional to the weight. In Figure 5 the slope of the lines increases with increasing testicular weight. This indicates that enzyme specific activity increases as the testicular size increases.

The specific enzyme activity is expressed as percent conversion per hour per mg of tissue. These data were plotted versus gonadal




Figure 3 Effect of substrate concentration on the velocity of the  $17\beta$ -hydroxysteroid dehydrogenase reaction in phalarope gonadal tissues.

----- ovarian tissue  
———— testicular tissue

Table 3. Effect of varying ovarian weight on conversion of androstenedione substrate to testosterone

Flask No.	Ave. ovarian wt.(mg)	Amt. tissue/flask(mg)	Incub. time (min.)	% recov.of Test.	% initial A* radioact.		
					T** formed	Others <sup>2</sup>	A* remaining
1	37.0	14.8	20	91.95	2.54	0.14	78.69
2	"	"	20	88.24	2.18	0.28	84.76
3	66.0	20.6	0	69.25	1.56	0.21	83.71
4	"	"	10	78.29	2.98	0.20	84.51
5	"	"	20	82.02	5.95	0.49	82.84
6	"	"	0	97.15	1.91	0.13	88.60
7	"	"	10	94.28	3.16	0.22	87.46
8	"	"	20	95.13	6.52	0.46	84.39
9	147.4	22.7	0	88.19	0.54	0.09	92.08
10	"	"	10	81.50	3.06	0.55	81.78
11	"	"	20	93.66	6.19	2.24	82.38
12	"	"	0	80.70	0.38	0.12	89.22
13	"	"	10	88.07	3.20	0.96	87.34
14	"	"	20	89.33	10.02	2.72	77.42
15*	167.7	25.0	0	80.52	4.89	0.45	80.90
16*	"	"	10	84.78	4.86	0.13	84.69
17*	"	"	20	100.83	5.96	0.26	83.14
18	"	"	0	103.33	0.39	0.07	91.11
19	"	"	10	101.32	2.84	0.18	95.05
20	"	"	20	102.00	8.36	0.56	79.31
21*	"	"	0	95.50	1.67	0.13	85.92
22*	"	"	10	101.93	3.10	0.09	89.18
23*	"	"	20	86.94	6.15	0.16	83.63
24	"	"	0	106.51	0.31	0.05	89.50
25	"	"	10	102.79	2.61	0.09	92.13
26	"	"	20	109.65	4.57	0.14	88.84
27	219.0	25.0	0	97.53	0.25	0.08	92.18
28	"	"	10	104.56	1.90	0.28	91.51
29	"	"	20	107.33	3.40	0.22	93.81
30	"	"	0	102.38	0.21	0.04	95.11
31	"	"	10	111.76	1.64	0.08	89.96
32	"	"	20	107.73	3.49	0.23	86.98

A\* = Androstenedione.

T\*\* = Testosterone (data corrected for % of recovery).

Others\* = Area lying between testosterone and androstenedione on the initial paper chromatogram of incubation media extracts. Both (Others) and (Androstenedione remaining) are raw data.

\* = Incubation flask contained double amount of substrate.

Table 3. Effect of varying ovarian weight on conversion of androstenedione substrate to testosterone (cont.)

Flask No.	Ave. ovarian wt.(mg)	Amt. tissue/flask(mg)	Incub. time (min.)	% recov.of Test.	% initial A* radiact.		
					T** formed	Others*	A* remaining
33	224.0	25.0	0	97.67	0.35	0.07	95.98
34	"	"	10	106.51	3.72	0.16	87.74
35	"	"	20	98.06	8.12	0.14	85.42
36	"	"	0	99.99	0.30	0.06	91.04
37	"	"	10	95.73	4.56	0.23	89.07
38	"	"	20	110.91	8.26	0.20	79.63
39	302.6	25.0	0	101.91	0.42	0.09	94.01
40	"	"	10	96.72	1.91	0.20	87.97
41	"	"	20	103.15	4.33	0.35	80.27
42	"	"	0	100.15	0.23	0.04	94.13
43	"	"	10	95.84	1.72	0.12	92.85
44	"	"	20	100.65	3.66	0.26	86.46
45	500.8	50.0	0	93.44	0.49	0.07	93.92
46	"	"	10	97.12	4.67	0.30	89.20
47	"	"	20	96.68	9.76	0.36	76.81
48	"	"	0	92.63	0.41	0.05	90.29
49	"	"	10	91.36	4.13	0.30	91.45
50	"	"	20	93.24	10.74	0.29	81.45
51	2323.8	100.0	0	92.14	0.18	0.05	92.85
52	"	"	10	89.45	2.71	0.15	91.34
53	"	"	20	99.62	9.34	0.44	81.87
54	"	"	0	95.63	0.21	0.04	91.18
55	"	"	10	81.29	2.72	0.22	88.49
56	"	"	20	88.68	5.64	0.28	84.31

A\* = Androstenedione.

T\*\* = Testosterone (data corrected for % of recovery).

Others\* = Area lying between testosterone and androstenedione on the initial paper chromatogram of incubation media extracts.  
Both (Others) and (Androstenedione remaining) are raw data.

Table 4. Effect of varying testicular weight on conversion of androstenedione substrate to testosterone

Flask No.	Ave. testes wt.(mg)	Amt. tissue/flask(mg)	Incub. time (min.)	% recov.of Test.	% initial A* radioact.		
					T*** formed	Others*	A* remaining
57	443.0	50.0	0	87.16	0.06	0.07	91.43
58	"	"	10	94.25	8.05	0.38	81.09
59	"	"	20	108.48	21.10	0.30	69.42
60	"	"	0	84.90	0.06	0.02	89.28
61	"	"	10	90.66	8.62	0.13	84.27
62	"	"	20	96.22	21.30	0.18	73.72
63*	325.0	25.0	0	76.82	0.12	0.08	87.80
64*	"	"	10	85.51	1.50	0.07	80.16
65*	"	"	20	83.21	3.94	0.22	80.37
66**	"	"	0	91.47	0.01	0.04	94.48
67**	"	"	10	88.91	1.16	0.05	88.48
68**	"	"	20	93.30	4.66	0.07	73.36
69*	"	"	0	87.93	0.14	0.05	85.48
70*	"	"	10	89.21	1.28	0.49	82.56
71*	"	"	20	82.13	4.30	0.47	81.50
72**	"	"	0	84.24	0.01	0.03	88.10
73**	"	"	10	101.01	1.25	0.20	85.94
74**	"	"	20	102.18	3.41	0.14	84.22
75**	217.0	25.0	0	102.27	0.06	0.04	92.58
76**	"	"	10	111.40	2.35	0.15	84.14
77**	"	"	20	106.13	3.21	0.20	84.02
78**	"	"	0	101.36	0.06	0.02	93.16
79**	"	"	10	108.11	0.71	0.06	89.04
80**	"	"	20	111.76	2.42	0.13	90.82

\* = double amount of substrate

\*\* = half amount of substrate

A\* = Androstenedione

T\*\*\* = Testosterone (data corrected for % of recovery)

Others\* = Area lying between testosterone and androstenedione on the initial paper chromatogram of incubation media extracts. Both (Others) and (androstenedione remaining) are raw data.



Table 5. Effect of gonadal weight on  $17\beta$ -hydroxysteroid dehydrogenase activity

Homog. No.	Ave. gonadal wt.(mg)	Amount substrate/flask ( $\mu$ M)	Ave.** specific enzyme activity	Ave.*** total enzyme activity
1	37.0	25.0	0.51	18.86
2	66.0	"	0.59	38.63
3	147.4	"	0.75	109.70
4	167.7	"	0.53	88.85
4	"	50.0	0.54	89.70
5	219.0	25.0	0.38	83.25
6	224.0	"	0.92	205.50
7	302.6	"	0.42	125.70
8	500.8	"	0.57	286.85
9	2323.8	"	0.16	370.20
10*	443.0	"	1.18	520.70
11*	325.0	12.5	0.42	136.25
11*	"	50.0	0.43	136.50
12*	217.0	12.5	0.32	67.85

\* = testicular tissue

\*\* = Average % conversion/hr./mg of gonadal tissue used for incubation

\*\*\* = Specific enzyme activity x total gonadal weight




Figure 4  $17\beta$ -hydroxysteroid dehydrogenase activity per 100 mg of incubation tissue of different ovarian weight.  
# 1,2,3,4,5,6,7,8,9 = Homogenate No. of different ovaries in order of increasing ovarian weight(see Table 1, p. 79).




Figure 5 Incubation time (min.)  
17 $\beta$ -hydroxysteroid dehydrogenase activity per  
100 mg of incubation tissue of different  
testicular weight.  
#10,11,12 = Homogenate No. of different paired  
testes in order of decreasing testicular weight  
(see Table 1, p.79 )

weight. In general, the specific enzyme activity in ovarian tissue tended to increase then decrease as the ovarian weight increased from 37.0 mg to 2323.8 mg (Figure 6). However, there is a considerable variation of the specific activity in the 219 mg to 500.8 mg tissue weight range. Furthermore, a marked decrease of enzyme activity is observed in the largest ovary. In the testes incubations, the specific enzyme activity increases with testicular weight (Figure 7). This result corresponds to the hypothesis.

The total enzyme activity is expressed as average percent conversion per hour per gonadal weight, i.e., specific enzyme activity x total gonadal weight. Figure 8 shows that the total enzyme activity increases as ovarian size increases from 37.0 mg to 2323.8 mg. There is a variation in activity in the 140-300 mg tissue weight range. The total testicular enzyme activity as shown in Figure 9 increases as the gonad size increases. There is a remarkable increasing in the total testicular enzyme activity as the testes approach maximal weight. It is interesting to observe that the curve of total enzyme activity in the testes does not follow the same pattern as that in the ovaries. The former shows a concave upward curve, whereas the latter follows a partial concave downward pattern. It appears that the total enzyme activity tended to increase more rapidly than that in ovaries in the latter stages of gonadal development (Figures 8 and 9). This finding confirms part of original hypothesis.

### C. Production identification

Figure 2 shows the tracing of the first paper chromatographic




Figure 6 Effect of ovarian weight on the specific activity of  $17\beta$ -hydroxysteroid dehydrogenase




Figure 7 Effect of testicular weight on the specific activity of  $17\beta$ -hydroxysteroid dehydrogenase




Figure 8 Effect of ovarian weight on the total activity of  $17\beta$ -hydroxysteroid dehydrogenase




Figure 9 Effect of testosterone weight on the total activity of  $17\beta$ -hydroxysteroid dehydrogenase


separation of radioactive metabolites isolated from incubations media. Since the mobility of fraction 1 corresponded to that of authentic testosterone, this area on the paper chromatogram was eluted and further identification of this unknown steroid was performed. The procedures of isolation and identification of this metabolite are indicated in Figure 10. The  $R_f$  values of metabolic product No. 1 and its derivatives are presented in Table 6. The ratios of  $^3\text{H}/^{14}\text{C}$  found in this metabolite and its derivatives are shown in Table 7.

Fraction 1 showed a monoacetate derivative upon acetylation and was partially converted to the parent compound after saponification. Only androstenedione was obtained when the parent compound recovered after saponification was oxidized with  $\text{CrO}_3$  in glacial acetic acid. The chromatographic mobilities of metabolite and its derivatives were identical to those of authentic testosterone, or testosterone with similar treatment, in several thin-layer and paper chromatographic systems.

There was no significant variation of the  $^3\text{H}/^{14}\text{C}$  ratio of the parent compound recovered from saponification, of the acetate derivative, and of the oxidation product. However, the parent compound recovered after saponification had a slightly lower  $^3\text{H}/^{14}\text{C}$  ratio than did the original acetate derivative (Table 7).

On the strength of the chromatographic evidence of the parent compound, the acetate derivative, the oxidation product and the  $^3\text{H}/^{14}\text{C}$  ratio data, the metabolite 1 was identified as testosterone.

Figure 10. Flow sheet for the isolation and identification of testosterone formed from androstenedione substrate as described in the text.



system 1 (TLC) = cyclohexane:ethyl acetate (50:50)v/v, thin layer chromatography

system 2 (ITLC) = ethylacetate:benzene (1:4)v/v, instant thin layer chromatography

system HB(PC) = heptane:benzene (1:1)/formamide, paper chromatography

system B(PC) = benzene/formamide, paper chromatography

AC<sub>2</sub>O = acetic anhydride

HOAc = acetic acid



Table 6. Chromatographic identification of metabolite I.

	R <sub>f</sub> Values						
	Standards**		Metabolite I				
	Ac	Andro	Parent Cpd.	Acetate deriv.	Sapon. Acetate	Oxid. Prod.	
TLC-1	0.178 ±0.003*	0.648 ±0.032	0.178 ±0.004				
ITLC-2		0.598 ±0.003		0.581 ±0.048			
PC-1	0.150 ±0.006	0.803 ±0.048	0.420 ±0.020	0.822 ±0.081	0.154 ±0.009	0.451 ±0.022	
PC-2			0.671 ±0.074			0.723 ±0.053	

Chromatographic systems:

- TLC-1 = thin layer chromatography; cyclohexane:ethyl acetate (50:50) v/v  
 ITLC-2 = instant thin layer chromatography; ethyl acetate:benzene (1:4)v/v  
 PC-1 = paper chromatography; heptane:benzene(1:1)/formamide  
 PC-2 = paper chromatography; benzene/formamide

\* Standard deviation

\*\*Abbreviations:

- T = Testosterone  
 Andro = Androstenedione  
 Ac = Acetate  
 Sapon = Saponified  
 Oxid = Oxidation  
 Cpd = Compound  
 deriv = derivative  
 prod = product

Table 7.  $^3\text{H}/^{14}\text{C}$  ratios of metabolite I

Group* No.	Acetate derivative	$^3\text{H}/^{14}\text{C}$ ratio Saponified Acetate	Oxidation product
1	24.92	22.74	23.07
2	13.76	12.67	12.89
3	11.82	8.33	8.21
4	15.24	13.49	13.59
5	27.25	18.37	18.38
6	13.31	12.07	12.13
7	29.32	26.98	27.30
8	11.67	10.34	10.55
9	17.03	15.48	15.72
10	6.29	5.07	5.21
11	20.04	17.31	17.54
12	8.34	7.22	7.42

\* Homogenate No. (see Table 1, p. 75)

## V. DISCUSSION

From the kinetic point of view, it is important to study the initial reaction velocity with a substrate concentration which is sufficient to saturate the enzyme, since the reaction proceeds at maximal velocity only under these conditions. To investigate whether the reduction of 17-ketone of androstenedione was proceeding at maximal rate with a 25  $\mu$ M substrate concentration, an incubation was done using twice the amount of this substrate concentration. It was found that 25  $\mu$ M androstenedione was enough for the reaction to proceed at a maximal rate under the experimental conditions used in the ovarian tissue. With testicular tissue, the reaction rates were the same with the substrate concentration of 12.5 and 50.0  $\mu$ M (Figure 3). However, the ovarian tissue (167.7 mg ovary) used to determine if a 25  $\mu$ M substrate concentration gave maximal reaction rates did not contain the highest total enzyme units per flask. The total arbitrary enzyme units of this enzyme were 13.5 u (0.54 u/mg x 25 mg) whereas the highest total enzyme units per flask were 28.5 u (0.57 u/mg x 50 mg). In the testicular tissue, the highest total number of enzyme units per flask, 59.0 u (1.18 u/mg x 50 mg), was about six times that of the flasks, 10.5 u (0.42 u/mg x 25 mg), incubated with two different substrate concentrations (Table 5). Therefore, it might be possible that in those incubation flasks containing more than 13.5 units in the ovarian tissue or 10.5 units in the testicular tissue, the reaction velocity was sub-maximal and the estimates of enzyme activity would be low. However, since the  $K_m$  values of 17 $\beta$ -hydroxysteroid dehydrogenase from other tissue lies

between  $1 \times 10^{-5}$  to  $10^{-6}$  (27), and since the substrate concentration used in these experiments was  $2.5 \times 10^{-5}$  M, it appears that the substrate concentration is probably greater than the  $K_m$  of the enzyme in these experiments.

It should be pointed out that since only conversion of exogenous substrate to product was measured, any marked difference in the concentration of endogenous androgens might alter the level of enzyme activity calculated in these experiments. However, since the substrate concentration of androstenedione used in these experiments was  $0.05 \mu\text{mole}$  ( $14.3 \mu\text{g}$ ) in homogenized gonadal tissues (25, 50 or 100 mg), it was about hundred to twenty-five times that of endogenous androgens reported in the phalarope ovarian and testicular tissues\* (26). Therefore, the low levels of tissue androgens might not cause significant variation in the enzyme activity calculated in these experiments.

Talalay and Marcus (52), Langer et al. (35) and Jarabak et al. (27) studied substrate specificity of bacterial and human placental  $17\beta$ -hydroxysteroid dehydrogenase and found that these enzymes could catalyze both the oxidation reaction of testosterone and  $17\beta$ -estradiol to androstenedione and estrone, respectively. Some rate difference in these two reactions was observed. However, since the enzymes examined in their experiments were only partially purified, it is debatable whether these two reactions are mediated by the same enzyme.

---

\* The levels of endogenous androgens in phalarope gonadal tissues are as follows:

Ovary : A =  $5.38 \times 10^{-3}$  ug/mg; T =  $1.16 \times 10^{-3}$  ug/mg

Testis: A =  $3.96 \times 10^{-3}$  ug/mg; T =  $1.26 \times 10^{-3}$  ug/mg

A = Androstenedione; T = Testosterone

All these data are the highest values reported in the paper of Höhn and Cheng (26).

From a histochemical point of view, if only one protein exists, one would expect similar cellular localization of the enzyme. On the other hand, dissimilar histochemical localization of the staining reaction with various substrates catalyzed by the enzyme would indicate the existence of more than one enzyme. The difference demonstrated by Kellogg and Glenner (31) in the localization of NAD and NADP-linked dehydrogenases indicates that the enzymes are separate and distinct. This conclusion is supported by the report of Hagerman and Villee (25). They reported the separation of the placental NAD and NADP-linked  $17\beta$ -hydroxysteroid dehydrogenases. Koide and Mitsudo (32) found that the staining reaction of the placental NAD and NADP-linked  $17\beta$ -hydroxysteroid dehydrogenase with testosterone was restricted to the vessels which differed from the localization of  $17\beta$ -estradiol with NAD. Botte et al. (12) also reported that the NADP-dependent placental  $17\beta$ -hydroxysteroid dehydrogenase in mouse was present in the first trophoblastic generation giant cells and in the endodermal cells of the inverted yolk sac placenta only using  $17\beta$ -estradiol as substrate and not with testosterone as substrate. These difference in the localization of the staining reaction with various  $17\beta$ -hydroxyl steroids suggested that NAD and NADP-linked dehydrogenase for testosterone and  $17\beta$ -estradiol are separate enzymes.

Davenport and Mallette (19) investigated the pH effect on the activity of rabbit ovarian  $17\beta$ -hydroxysteroid dehydrogenase with either testosterone or  $17\beta$ -estradiol as substrate and NADP as cofactor. The enzyme activity-pH curves with these two substrates were different.


Furthermore, they also reported the different ratios of activity with NADP to those with NAD for testosterone (8.0) and  $17\beta$ -estradiol (2.8). This might suggest that there are distinct enzymes catalyzing the dehydrogenation of these two  $17\beta$ -hydroxyl steroids. Therefore, the total activity of  $17\beta$ -hydroxysteroid dehydrogenase measured in the present experiments could reflect the level of secretion of testosterone in the avian gonadal tissue.

Figure 6 shows that the specific activity of  $17\beta$ -hydroxysteroid dehydrogenase in the ovary appears to increase and then decrease with ovarian weight. Variation is shown in the 224 mg ovary. This might be due to individual variation. A remarkable decrease of specific activity is found in the largest ovary (Figure 6). The total enzyme activity shows the reverse result (Figure 8). This is probably due to quite a large portion of acellular material in the larger size of ovaries resulting from the development of the eggs. Therefore, the enzyme specific activity decreases whereas the total activity of enzyme increases with increasing ovarian weight.

In the original hypothesis, it was suggested that there might be a decrease in the total testosterone  $17\beta$ -HSD activity as the size of ovary increases. Since the birds were shot in early May, ovarian weight was increasing or near maximum and it might be suspected that ovarian androgen production would be reduced to permit follicular development (2,30,56). However, the total enzyme activity in ovarian tissue obtained in the present experiments tended to increase with increasing size of ovaries. These results partially agree with the

findings of Höhn and Cheng (26). They reported the endogenous androgen levels in phalarope ovarian tissue increased during the pre-laying, laying and post-laying period. On the contrary, the present experimental results are at variance with the reports of Fevold and Pfeiffer (23) and some other workers (30,51,1). These investigators used a substrate prior to androstenedione in the metabolic pathway and found that the androstenedione to testosterone ratio was greater than one in the ovarian tissue. However, this ratio depends mainly on the activity of  $17\beta$ -hydroxysteroid dehydrogenase present in the gland. The high ratio might indicate low activity of  $17\beta$ -HSD present in the gland.

Estrogens can be biosynthesized from either androstenedione or testosterone as indicated in the following diagram:



If pathway a and b are predominant in phalarope ovarian tissue, a high level of testosterone could be used as the precursor for the synthesis of estrogen. On the other hand, if pathway c is the dominant reaction in estrone biosynthesis, a low activity of testosterone  $17\beta$ -HSD would be expected. In placental tissue (57), 19-hydroxyandrostenedione is an obligatory intermediate and 19-hydroxylation is the rate limiting step in the formation of estrogens from androstenedione. However, there is no evidence whether this 19-hydroxyandrostenedione compound is also an obligatory intermediate of estrogen synthesis in avian ovarian tissue. Further knowledge concerning the aromatizing steps of estrogens bio-

synthesis from C-19-compound in the avian ovary is needed. Whether testosterone is the predominant precursor of estrogen biosynthesis in the phalarope ovary is unknown at this time, since what is true of one tissue may not be true of the other.

The increasing total enzyme activity with the size of phalarope ovary poses a problem concerning the function of testosterone in ovulation on the one hand and its effect on the total gonadotrophin secretion on the other.

Breneman (14) observed that there was a spurt in comb growth of pullet from 110 days through 126 days of post-patching. The comb achieves a size twelve times that recorded at 106 days. Besides, the ovarian growth between 115 and 126 days of age increases almost twelve times from 495.7 to 571.1 mg and potency of anterior pituitary increases twice amount between 115 to 126 days. Further investigation of testosterone propionate (TP) effect on birds disclosed that TP has a pronounced effect on pullet comb growth but its effect on ovarian and pituitary weight was not significant. However, the administration of combination of  $17\beta$ -estradiol and testosterone at various dosage levels showed that little effect is produced when either of the two gonadal hormones is administered alone, but when estrogen and androgen are administered simultaneously, maximum stimulation of comb, ovarian weight, oviduct and pituitary occurs. Therefore, he concluded that ovarian secretion of androgen in pullets precedes ovarian growth. Androgen and estrogen might be present coincidentally with the beginning of maximal ovarian growth and the gonadotrophin content of pituitary



is not inhibited by the gonadal hormones. In examination of his experiments, it is found that he did not assay the relative potency of follicle stimulation hormone (FSH) and luteinizing hormones (LH) nor determine the time of estradiol and testosterone secretion. Therefore, whether testosterone could stimulate both gonadotrophins or might inhibit one or the other is doubtful since testosterone may differentially affect pituitary content of FSH and LH (49). It is also questionable whether estrogen and androgen will be secreted simultaneously at the beginning of maximum ovarian growth. Furthermore, the effect of gonadal hormones on the potency of gonadotrophin in his experiments is dose dependent. A combination of 1.0  $\mu$ g  $17\beta$ -estradiol and 1.0  $\mu$ g testosterone decreased the potency of the pituitary. Therefore, the stimulation effect of testosterone on the pituitary gonadotrophin content in the presence of estrogens should be reconsidered.

It should be emphasized that some genetic and physiological differences exist between the phalarope and the pullet. First, there is no comb in the phalarope. Secondly, the phalarope only have four eggs per clutch instead of laying about 300 eggs per year as does the pullet. Thirdly, the phalarope shows sex reversal behavior. There might be considerable differences in the function of testosterone in the phalarope ovary as compared with that of the pullet. However, some conflicting reports have been demonstrated by other workers. Nelson and Stabler (39) administered TP to young female sparrow hawks and found that ovaries were not stimulated, although the oviducts were enlarged. Greep and Jones (24) reported that administration of testo-

sterone to rats results in a decrease in pituitary and ovarian weight but that FSH content of the pituitary is increased. Testosterone has been found to cause a decrease in estrogen secretion as well as a decrease in ovarian weight in hypophysectomized prepuberal rats (33) and in parabiotic rats (49). Since no estrogen determination was done in the present experiments and no assay of gonadotrophin was performed either, the function of testosterone in the phalarope ovary can not be solved now. It is thought that it might augment with FSH and LH secretion to stimulate ovarian development and estrogen secretion. However, further knowledge of the pituitary-gonadal hormones relationship and the influence of gonadal hormones on avian ovarian development needs further investigation.

Both the specific activity and total activity of  $17\beta$ -hydroxysteroid dehydrogenase in the testicular tissue increased with the increasing testicular size (Figures 7 and 9). There is considerably more enzyme activity present in the largest testes as compared with the other two groups of small testes. These results confirmed the prediction of hypothesis concerning androgen formation by male phalaropes during the reproductive seasons. Furthermore, the testes appear to have a greater capacity than the ovary for synthesizing the more active androgen (testosterone), in the later stages of gonadal development (Figures 8 and 9), and agree with the work of Fevold and Pfeiffer (23). During the breeding season the increase of testosterone production will stimulate spermatogenesis of male phalaropes (28), and since testosterone and prolactin are necessary for the development of

the brood patch, found only in the male of the species, it would be expected that the male would increase the production of testosterone as the testicular size increases.

The identity of testosterone was established by several criteria. One of them was by measuring the  $^3\text{H}/^{14}\text{C}$  ratio of the acetate derivative, the parent compound and the oxidation product. It was found that the  $^3\text{H}/^{14}\text{C}$  ratio of the acetate derivative was constantly higher than that of the parent steroid recovered from saponification (Table 7). The most likely explanation is that the tritium label at the 1,2-position of testosterone is unstable in the alkali saponification conditions, due to the enolization of 3-ketone group. However, there was no significant variation in the  $^3\text{H}/^{14}\text{C}$  ratio of the parent compound, recovered after saponification, and the oxidation product. The result confirms the identity of the metabolite with testosterone.

## VI. SUMMARY

Various weights of phalarope ovarian and testicular tissue homogenates were incubated with androstenedione-4-<sup>14</sup>C in a Krebs-Ringer phosphate buffer (pH 7.35) with ATP, DPN, TPN, sodium fumarate, nicotinamide, glucose-6-phosphate, glucose and glucose-6-phosphate dehydrogenase as cofactors and additives. The incubations were carried out at 41°C for 0, 10 and 20 minutes. The radioactive steroids formed were extracted and isolated. The activity of 17 $\beta$ -hydroxysteroid dehydrogenase was calculated from the rate of conversion of androstenedione to testosterone.

The specific enzyme activity in the ovarian tissue first increases and then decreases with increasing size of ovary, whereas the total enzyme activity in the ovarian tissue tends to increase with ovarian weight. Both the specific activity and the total activity in the testicular tissue increase as the size of testes increases. The testes appear to have a greater capacity than the ovary for reducing androstenedione to testosterone in the later stages of gonadal development.

VII. BIBLIOGRAPHY

1. Aakvaag, A. and Eik-Nes, K. B. 1964. Metabolism in vivo of  $7\alpha$ - $^3$ H-pregnenolone by the ovary of dogs treated with follicle stimulation hormone.
2. Barraclough, C. A. and Gorski, R. A. 1961. Evidence that the hypothalamus is responsible for androgen induced sterility in the female rat. *Endocrinology*. 68, 68.
3. Bartholomew, G. A. Jr. 1949. The effect of light intensity and day length on reproduction in the English sparrow. *Bull. Museum. Comp. Zool.* 101, 433.
4. Benoit, J. 1935. Role de l'hypophyse dans l'action stimulant de la lumiere sur le developpement testiculaire chez le canard. *Compt. Rend. Soc. Biol.* 118, 672.
5. Benoit, J. 1936. Stimulation of the hypophysis and genital glands in the duck by electric light. *Anat. Record*, suppl. 67, 81.
6. Benoit, J. and Ott, L. 1944. External and internal factors in sexual activity: effect of irradiation with different wave-lengths on the mechanism of photostimulation of the hypophysis and testicular growth in the immature duck. *Yale J. Biol. Med.* 17, 27.
7. Bent, A. C. 1960. "Life Histories of North American Birds." vol. 1, p. 259. Harper, New York.
8. Bissonnette, T. H. 1930. Studies on the sexual cycle in birds I. Sexual maturity, its modification and possible control in the European starling (*Sturnus vulgaris*). *Am. J. Anat.* 45, 1289.
9. Bissonnette, T. H. 1931. Studies on the sexual cycle of birds V. Effects of light of different intensities upon the testis activity of the European starling (*Sturnus vulgaris*). *Physiol. Zool.* 4, 453.
10. Bissonnette, T. H. 1932a. Studies on the sexual cycle of birds. VI. Effect of white, green and red light of equal luminous intensity in the testis activity of European starling (*Sturnus vulgaris*). *Physiol. Zool.* 5, 92.
11. Bissonnette, T. H. 1932b. Light and diet as factors in relation to sexual periodicity. *Nature* 129, 612.
12. Boote, V., Tramontana, S. and Chieffi, G. 1968. Histochemical distribution of some hydroxysteroid dehydrogenases in the placenta, foetal membranes and uterine mucosa of the mouse. *J. Endocrinol.* 40, 189.

13. Breneman, W. R. 1936. The effect on the chick of some gonadotrophic hormones. *Anat. Record* 64, 211.
14. Breneman, W. R. 1956. Reproduction in birds: the female. *Mem. Soc. Endocrin.* 4, 94.
15. Burger, J. W. 1940. Further studies on the relation of the daily expose to light to the sexual activation of the male starling (*Sturnus vulgaris*). *J. Exptl. Biol.* 84, 351.
16. Burger, J. W. 1943. Some effects of colored illumination on the sexual activity of the male starling. *J. Expt. Zool.* 94, 161.
17. Burger, J. W. 1949. A review of experimental investigations on seasonal reproduction in birds. *Wilson Bulletin* 61, 211.
18. Christ, R. D. and Warren, J. C. 1966. Transhydrogenation in the human placenta. *Acta Endocrinol.* 53, 205.
19. Davenport, G. R. and Mallette, L. E. 1966. Some biochemical properties of rabbit ovarian hydroxysteroid dehydrogenase. *Endocrinology.* 78, 672.
20. Davenport, G. R., Norris, J. L. and Rennie, P. I. C. 1966. Histochemical studies of hydroxysteroid dehydrogenase activity in mammalian reproductive tissues. *Endocrinology* 78, 667.
21. Dennis, P. M., Hughes, A. and Thomas, G. H. 1968.  $17\beta$  and  $20\alpha$ -hydroxysteroid dehydrogenase activity in the rabbit. *J. Endocrinol.* 40, 257.
22. Fevold, H. R. 1961. In vitro progesterone metabolism by avian testicular tissue. (Ph. D. thesis)
23. Fevold, H. R. and Pfeiffer, E. W. 1968. Androgen production in vitro by phalarope tissue homogenates. *Gen. and Comp. Endocrinol.* 10, 26.
24. Greep, R. O. and Chester, J. I. 1950. Recent Progress of Hormone Research. 5, 197.
25. Hagerman, D. D. and Vिलlee, C. A. 1959. Separation of human placental estrogens-sensitive tranhydrogenase from estradiol- $17\beta$ -dehydrogenase. *J. Biol. Chem.* 234, 2031.
26. Höhn, E. O. and Cheng, S. C. 1967. Gonadal steroid hormone in Wilson's phalarope (*Steganopus tricolor*) and other birds in relation to plumage and sex behavior. *Gen. and Comp. Endocrinol.* 8, 1.

27. Jarabak, J., Adams, J. A., Williams-Ashman, H. G. and Talalay, P. 1962. Purification of a  $17\beta$ -hydroxysteroid dehydrogenase function human placenta and studies on its transhydrogenase function. *J. Biol. Chem.* 237, 3069.
28. Johns, J. E. and Pfeiffer, E. W. 1963. Testosterone-induced incubation patches of phalarope birds. *Science* 140, 1225.
29. Johns, J. E. 1964. Testosterone-induced nuptial feathers in phalaropes. *Condor* 66, 449.
30. Kase, N., Forchielli, E. and Dorfman, R. I. 1961. *In vitro* production of testosterone and androstenedione in a human ovarian homogenate. *Acta Endocrinol.* 37, 19.
31. Kellogy, D. A. and Glenner, G. G. 1960. Histochemical localization of human term placental  $17\beta$ -estradiol dehydrogenases: implications of the transhydrogenase reaction. *Nature* 187, 763.
32. Koide, J. J. and Mitsudo, S. M. 1966. Histochemical study of  $3\beta$  and  $17\beta$ -hydroxysteroid dehydrogenase in human term placenta. *Endocrinology* 78, 403.
33. Krahenbuhl, C. and Desaulles, P. A. 1964. The action of sex hormones for gonadotrophin induced ovulation in hypophysectomized prepuberal rats. *Acta Endocrinol.* 47, 457.
34. Langer, L. J., and Engel, L. L. 1958. Human placental estradiol- $17\beta$ dehydrogenase I. *J. Biol. Chem.* 233, 583.
35. Langer, L. J., Alexander, J. W. and Engel, L. L. 1959. Human placental estradiol- $17\beta$ dehydrogenase. *J. Biol. Chem.* 234, 2609.
36. Lofts, B. and Marshall, A. J. 1958. An investigation of the refractory period of reproduction in male birds by means of exogenous prolactin and follicle stimulating hormones. *J. Endocrinol.* 17, 91.
37. Long, C., King, E. J. and Warren, S. M. 1961. *Biochemist's Handbook*. p. 351, D. Van Nostrand Company, Inc. Princeton.
38. Müller, A. H. 1949. Potentiality for testicular recrudescence during the annual refractory period of the golden-crowned sparrow. *Science* 109, 546.
39. Nelson, O. E. and Stabler, R. M. 1940. The effect of testosterone propionate on the early development of the reproductive ducts in the female sparrow hawk (*Falco sparverius*). *J. Morph.* 66, 277.

40. Riley, G. M. 1936. Light repulation of sexual activity in the male sparrow (*Passer domesticus*) Proc. Soc. Exptl. Biol. Med. 34, 331.
41. Riley, G. M. and Witschi, E. 1938. Comparative effects of light stimulation and administration of gonadotrophic hormones on female sparrows. Endocrinology 23, 618.
42. Ringeon, A. R. 1942. Effects of continuous green and red light illumination on gonadal response in the English sparrow (*Passer domesticus*) Am. J. Anat. 71, 99.
43. Romanoff, A. L. and Romanoff, A. J. 1949. The Avian Egg. first edition. N. Y. John Wiley and Sons, Inc.
44. Rowan, Wm. 1925. Relation of light to bird migration and developmental changes. Nature 115, 494.
45. Rowan, Wm. 1927. Migration and reproductive rhythm in birds. Nature 119, 351.
46. Rowan, Wm. 1928. Reproductive rhythm in birds. Nature 122, 11.
47. Schäfer, E. A. 1907. On the incidence of daylight as a determining factor in bird migration. Nature 27, 159.
48. Schoen, E. J. 1967.  $17\beta$ -Hydroxysteroid dehydrogenase activity in human testes. Acta Endocrinol. 56, 56.
49. Schuetz, A. W., Sager, D. B., and Meyer, R. K. 1964. Effect of testosterone on human chorionic gonadotrophin (HCG) -induced ovarian augmentation in parabiotic rats. Endocrinology 75, 384.
50. Sweat, M. L., Sammuell, L. T. and Lumry, R. 1950. Preparation and characterization of the enzyme which converts testosterone on androstenedione. J. Biol. Chem. 185, 75.
51. Sweat, M. L., Berliner, D. L., Bryson, M. J., Nabors, C. Jr., Haskell, J. and Holmstrom, E. G. 1960. The synthesis and metabolism of progesterone in the human and bovine ovary. Biochim. Biophys. Acta. 40, 289.
52. Talalay, P. and Marcus, P. I. 1956. Specific, kinetic and inhibition of  $\alpha$  and  $\beta$ -hydroxysteroid dehydrogenase. J. Biol. Chem. 218, 675.
53. Talalay, P. 1957. Enzymatic mechanisms in steroid metabolism. Physiol. Rev. 37, 362.
54. Talalay, P., Kawahara, F. S. and Prairie, R. L. 1963. Enzymic mechanism in steroid metabolism. Proc. Intern. Congr. Biochem. 7, 395.



55. Threadgold, L. T. 1960. A study of the annual cycles of the house sparrow at various latitudes. *Condor* 62, 190.
56. Weisz, J. and Lloyd, C. W. 1965. Estrogen and androgen production in vitro from 7-<sup>3</sup>H-progesterone by normal and polycystic rat ovaries. *Endocrinology* 77, 735.
57. Wilcox, R. B. and Engel, L. L. 1965. Kinetic studies on the role of 19-hydroxy-androst-4-ene-3,17-dione in estrogen biosynthesis. *Steroids, suppl.* I, 49.
58. Witschi, E. 1935. Seasonal sex characters in birds and their hormonal control. *Wilson Bulletin* 47, 177.
59. Wolfe, H. J. and Cohen, R. B. 1964. Histochemical study of glucose-6-phosphate dehydrogenase activity in the human fetal and prepubertal testes. *J. Clin. Endocrinol.* 24, 616.
60. Wolfson, A. 1952. The occurrence and repulation of the refractory period in the gonadal and fat cycles in the junco. *J. Exptl. Zool.* 121, 311.